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Androgen receptors (AR) and androgens play a pivotal role in the expression of the 
male phenotype. Several diseases, such as prostate cancer, are associated with alterations in 
AR function. Indeed, androgen blockade by drugs that prevent the production of androgens 
and/or block the action of the AR inhibits prostate cancer growth. However, resistance to the 
action of these drugs often occurs after 2-3 years as patients develop castration-resistant 
prostate cancer (CRPC). In CRPC, functional AR remains a key regulator. Hence, there is a 
constant need for the continuous development and discovery of new drug leads that targets 
the AR for treatment of prostate cancer.  
 
Here we report the discovery and development of prenylflavonoid icaritin a 
compound that co-targets the AR and AR splice variant (ARvs). Icaritin was found to inhibit 
transcription of key AR regulated genes, such as KLK3 (PSA) and TMPRSS2 and induce 
apoptosis in both androgen-sensitive and castration-resistant prostate cancer cells. Unlike 
bicalutamide, icaritin did not demonstrate agonistic activity in AR overexpressed cells. 
Mechanistically, icaritin impaired nuclear translocation and consequent AR binding to their 
androgen response elements. More importantly, icaritin promoted the degradation of both the 
AR and ARvs by binding to arylhydrocarbon-receptor (AhR) to mediate ubiquitin-
proteasomal degradation. Knockdown of AhR gene restored AR stability and prevented 
icaritin induced growth suppression. In clinically relevant murine models orthotopically 
implanted with androgen-sensitive and castration-resistant prostate cancer cells, icaritin was 
able to target the AR and ARvs, to inhibit AR signaling, tumor growth, and metastasis to 
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lumbar lymph nodes with no apparent induced-toxicity. Our results provide a mechanistic 
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Chapter 1:  Androgen receptor: structure, role in prostate cancer 
and drug discovery 
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1.1. Introduction  
The androgen receptor (AR) (NR3C4, nuclear receptor subfamily 3, group C, gene 4) 
belongs to the steroid hormone group of nuclear receptors with the estrogen receptor (ER), 
glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor 
(MR) [1-3]. The AR is a ligand-dependent transcription factor that controls the expression of 
specific genes. The binding of the AR to its native ligands 5α-dihydrotestosterone (DHT) and 
testosterone initiates male sexual development and differentiation. The current model of 
action of androgens and the AR is depicted in Figure 1A. Androgens such as testosterone are 
synthesized primarily by the Leydig cells in the testes, under the regulation of luteinizing 
hormone (LH) produced by the anterior pituitary gland. LH secretion is in turn regulated by 
gonadotropin-releasing hormone (GnRH). Once produced, testosterone mostly circulates 
bound to serum sex hormone-binding globulin (SHBG) and albumin [4, 5]. Only the free 
form enters prostate cells. Intracellularly, testosterone is converted into a more potent 5α-
reduced metabolite of testosterone, 5α-dihydrotestosterone (DHT), which promotes the 
growth and survival of prostate cells. DHT binds to the AR with high affinity, displaces heat-
shock proteins from the AR, drives the interaction between the N and C termini of the AR, 
and binds importin-α to translocate the AR into the nucleus [6]. In the nucleus, receptor 
dimers bind to androgen response elements (AREs) in the promoter regions of target genes, 
such as prostate-specific antigen (PSA, gene name KLK3) and transmembrane protease serine 
2 (TMPRSS2), etc., to which they recruit various coregulatory proteins to facilitate 
transcription, leading to responses such as growth and survival [7-12]. Male sexual 
differentiation fails to occur in the absence of androgens or without a functioning AR. A 
complete loss of AR function in males results in complete androgen insensitivity syndrome 
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[13, 14]. The role of the AR in the development and progression of prostate cancer has led to 
increasing interest in this nuclear receptor. Prostate cancer is predicted to be the leading 
cause of cancer-related death in men over the next decade in the United States [15]. The 
development and progression of prostate cancer depends on androgenic stimulation [11]. As 
such, prostate cancer is treated by depriving tumors of androgens such as DHT and 
testosterone or blocking their actions. However, the effect of this type of treatment is 
transient, as patients relapse after developing a castration-resistant form of the disease that is 
usually due to increased levels of AR expression or mutations that cause the AR to be 
resistant to antiandrogens. Many studies have focused on providing new insights into the 
mechanisms of AR action in prostate cancer. The determination of the three-dimensional 
crystal structures of the AR DNA binding domain (DBD) and ligand binding domain (LBD) 
has helped expand our understanding of this receptor by revealing fine molecular details. The 
importance of the AR has also led to the development of many predictive models of 
compound binding. Structural information and biochemical experiments have been used to 
aid rational drug design to improve existing drugs and develop new treatments for the 
disease.   The following chapter summarizes AR structure-function relationships, describes 
the role of the AR in prostate cancer and provides an extensive overview of the development 







Figure 1. Androgen and AR action. Genome organization of the human androgen 
receptor gene and the functional domain structure of the androgen receptor protein. A. 
Androgen and AR signaling in prostate cells. After testicular synthesis, testosterone is 
transported to target tissues such as the prostate and becomes converted to 
dihydrotestosterone (DHT) by 5-α-reductase. DHT binds to the ligand-binding pocket and 
promotes the dissociation of heat-shock proteins (HSPs) from the AR. The AR then 
translocates into the nucleus, dimerizes and binds to the androgen response element (ARE) in 
the promoter region of target genes such as prostate-specific antigen (PSA) and TMPRSS2. 
At the promoter, the AR is able to recruit members of the basal transcription machinery (such 
as TATA-box-binding protein (TBP) and transcription factor IIF (TFIIF)) in addition to other 
coregulators such as members of the p160 family of coactivators and cAMP-response 
element-binding protein (CREB))-binding protein (CBP). SHBG: serum sex hormone-
binding globulin. B. The androgen receptor gene has been mapped to the long arm of the X-
chromosome (locus: Xq11-q12). It contains eight exons interrupted by introns of varying 
lengths (0.7-2.6 kb) and codes for a protein of 919 amino acids consisting of several 
functional domains (N-terminal domain (NTD), DNA binding domain (DBD) and ligand 
binding domain (LBD); amino acid residue numbers are indicated above the AR protein 
domain map). Exon 1 codes for the NTD, exons 2 and 3 encode the DBD, and exons 4 to 8 
encode both the hinge and LBD.  
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1.2. AR structure and activity 
The AR gene is located on the X chromosome at the locus Xq11-Xq12 (Figure 1B) 
[16-18]. The protein coding region has 2757 nucleotides and spans eight exons, with introns 
that vary in size from 0.7 to 2.6 kb. The AR gene encodes a 110-kDa protein consisting of 
919 amino acids (Figure 1B) [19]. Like other members of the nuclear receptor family, the AR 
consists of three major functional domains; (i) the N-terminal domain (NTD) (residues 1-
555), followed by (ii) the DNA binding domain (DBD) (residues 555-623), and (iii) the C-
terminal ligand binding domain (LBD) (residues 665-919), which is connected to the DBD 
by a flexible hinge region (residues 623-665) (Figure 1B) [1]. All three domains are 
important for receptor function. The highly conserved DBD tethers the AR to promoter and 
enhancer regions of AR-regulated genes by direct DNA binding to allow the activation 
functions of the NTD and LBD to stimulate transcription of these genes. The activation 
function 1 (AF1, residues 142-485) in the NTD is constitutively active [20], whereas the 
activation function 2 (AF2), a hydrophobic surface composed of helices 3, 4 and 12 located 
in the LBD, is ligand dependent [21]. Currently, there is no structural information for the full 
length AR receptor. However, the structures of both the DBD and LBD have been solved 
separately, revealing critical details of the mechanism of action of this receptor.  
 
1.2.1. NTD 
The NTD accounts for more than half of the size of the AR (residues 1-555), and its 
entirety is encoded by exon 1. The sequence and lengths of the polyglutamine (CAG) and 
polyglycine (GGC) repeats of the AR NTD are highly variable in the human population [22-
24]. The length of the poly-Q repeat region has been shown to affect the folding and structure 
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of the AR-NTD [25]. Through biochemical and biophysical approaches, it was demonstrated 
that the removal of poly-Q repeats from the AR leads to a reduction in α-helical structure, 
whereas increasing the length of poly-Q repeats led to a modest increase in α-helical 
structure. The conformational changes in the NTD were proposed to have a concomitant 
impact on protein-protein interactions that is likely to explain the dependency of AR 
transcriptional activity on the repeat length [26]. As has been observed for many other poly-
Q repeat-containing proteins, shorter repeats generally impose a higher AR transactivation 
activity, whereas longer repeats cause reduced activity [27]. The deletion of the poly-Q tract 
causes a four-fold increase in AR activation function compared with the wild-type protein 
[28]. Thus far, the structure of the NTD has not been defined through X-ray crystallography; 
this is likely due to its highly disordered structure as described by circular dichroism 
spectroscopy studies and structure prediction algorithms [25, 29-32]. It has been proposed 
that intrinsically disordered proteins may undergo folding induced by the formation of 
specific protein-protein interactions [29, 30]. Taken together, the structural plasticity of a 
partially folded state is hypothesized to be an intrinsic property of the NTD that allows 
interactions with many structurally diverse binding partners [32, 33], such as coactivators of 
the P160 family [34], the basal transcription factors TATA-box binding protein and 
transcription factor IIF [35], and intramolecular interactions with the LBD.  Cooperative 
interactions with multiple binding partners enable high specificity by low-affinity 
interactions, which appear to be crucial for AR activity [32, 33].  
 
Deletion mutagenesis showed that, within the NTD region, a domain is required for 
full transcriptional activity [36].  Deletion studies have also helped to further demarcate the 
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AF1 region as the primary effector region of the NTD. The AF1 contains two separable 
transcription activation units (Tau-1 (amino acids 100-370) and Tau-5 (amino acids 360-
485)) that are indispensable for full activity of the AR (Figure 1B) [37]. Tau-1 contains a 
nuclear receptor box, FQNLF (amino acids 23-27), and Tau-5 contains the WHTLF motif 
(amino acids 433-437), both of which mediate direct ligand-dependent, interdomain 
interactions between the NTD and the LBD (termed an N/C interaction), which are important 
in regulating some, but not all, androgen-dependent genes [38-40]. The N/C interaction also 
helps to stabilize the AR dimer complex and to slow the rate of ligand dissociation [41, 42].  
 
1.2.2. DBD and hinge 
The DBD (residues 556-623) is a cysteine-rich region that is highly conserved among 
steroid hormone receptors (Figure 2A). According to the crystal structure of the AR DBD, 
each DBD monomer has a core composed of two zinc fingers (Figure 2B) (PDB: 1R4I), each 
of which consists of four cysteine residues that coordinate a zinc ion. The AR functions as a 
dimer that, like other steroid receptors, binds to promoter DNA response elements consisting 
of two equal, common hexameric half-sites (5΄-AGAACA-3΄) separated by a 3 base-pair 
spacer (IR3) [43]. The α-helix of the N-terminal zinc finger (the “recognition helix”) 
interacts directly with nucleotides in the hormone response element in the DNA major 
groove (Figure 2B). Three amino acid residues at the N terminus of this α-helix, named the 
P(roximal) box [glycine-serine-valine] (amino acids 577-581; GSCKV), are identical in the 
PR, GR and MR (Figure 2A and B) and are responsible for the specific recognition of the 
DNA response element [12]. A question that persisted was how steroid receptors achieve 
target specificity if the AR, PR, GR and MR bind a common DNA response element. Studies 
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have since identified selective androgen response elements (AREs) (e.g., 5’-GGTTCT-3’) 
that allow specific AR activation [44-46]. AREs have hexameric half-sites in a direct repeat 
orientation. Structural studies have confirmed that selectivity is achieved by receptor 
dimerization in a “head-to-head” fashion through the D(istal) box region (amino acid 596-
600; ASRND), which allows the AR to bind to direct repeat half-sites in its promoter (Figure 
2A and 2B) [43]. Because the DBD domains are highly conserved among the different 
steroid receptors, the reason why other steroid receptors do not recognize selective AREs is 
still a matter of debate. Based on crystallographic data, it was speculated that the AR 
contains an additional interface that stabilizes the AR dimer/ARE complex. In contrast, the 
dimerization strength of other steroid receptors would not be sufficient to retain stable 
binding to selective AREs [43, 47]. 
 
The nuclear localization signal (NLS) (residues 617-633) is localized at the junction 
between the DBD and the hinge region (residues 624-665) and is responsible for nuclear 
import of the receptor [48, 49]. Passive transport across the nuclear pore complex has been 
suggested to be feasible for proteins ranging from 20-40 kDa in size. In contrast, the AR, 
which is 110 kDa in size, requires help to be actively transported upon ligand binding. A 
recent study has suggested that androgen binding induces a switch that exposes the NLS and 
thereby allows the NLS to promote nuclear import through binding of importin-α [50]. 
Details of this interaction have been identified in the crystal structure of importin-α bound to 
the AR NLS (Figure 2C) (PDB: 3BTR) [51]. The NLS is composed of two clusters of basic 
amino acids separated by ten residues (617-RKCYEAGMTLGARKLKK-634), a motif that 
is highly conserved with that of the GR, MR and PR steroid hormone receptors. In the 
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complex, importin-α adopts a banana-shaped conformation in which its inner concave 
surface makes charge interactions with the second basic amino acid cluster of the NLS 
(Figure 2C). Apart from nuclear localization, the hinge region, and in particular its 629-
RKLKKL-634 motif, was also found to play a complex role in DNA binding, coactivator 
recruitment, and N/C interaction [52, 53] and is a target site for acetylation, ubiquitylation 







Figure 2. Structures of AR functional domains. A. Sequence alignment of the DNA 
binding domain of the androgen receptor (AR), progesterone receptor (PR), 
mineralocorticoid receptor (MR), and glucocorticoid receptor (GR) performed using 
ClustalW. * indicates the conserved cysteines involved in coordinating the zinc atom. B. 
Top, crystal structure of the AR DBD (pink) (PDB: 1R4I) complexed with its hormone 
response element (red/purple). The DBD contains two zinc fingers (grey). Each zinc ion is 
coordinated by four cysteines (yellow). One zinc finger is involved in direct DNA binding 
mediated by the P-box (orange), which recognizes the specific hormone response element 
half-site 5’-AGAACA-3’. The other zinc finger is involved in a “head-to-head” receptor 
dimerization through the D-box (green). Bottom, cartoon representation of the AR DBD. C. 
Crystal structure of an AR nuclear localization signal (NLS) peptide (amino acid 621-635) 
(orange) complexed with importin-α (yellow) (PDB: 3BTR). Residues from the major NLS 
site 629-RKLKKL-634 contribute to importin-α binding. D. Crystal structure of the AR 
ligand binding domain (purple) (LBD) (PDB: 1E3G). The LBD consists of 11 α-helices and 
two small, two-stranded β-sheets arranged in a typical three-layer antiparallel helical 




In contrast to the NTD, the AR LBD (residues 666-919) has been structurally well 
characterized by crystallography. The crystal structure of the AR LBD was first solved in the 
year 2000 [54], and subsequently, many other complex structures were deposited into the 
protein databank (PDB). The three-dimensional structure is arranged in a three-layer, 
antiparallel α-helical sandwich (PDB: 1E3G) fold that is characteristic of NR LBDs. The AR 
LBD consists of eleven α-helices and four short β strands forming two anti-parallel β-sheets 
(Figure 2D). The H1 and H3 helices form the first layer of the α-helical sandwich. Unlike 
other nuclear receptors, the AR does not have H2, which is instead replaced by a long 
flexible linker (Figure 2D). The middle layer is formed by H4, H5, the first β sheet, H8, and 
H9. The third layer is completed by H10 and H11. There is a ligand binding pocket (LBP) 
surrounded by the N termini of H3, H5 and H11. H12, which forms the core of the activation 
function 2 domain (AF2), acts as a lid to close the LBP upon agonist binding (Figure 2D).  
 
1.2.3.1. AR Ligands 
A large variety of small molecules has been discovered or engineered to interact with 
the AR [55-57]. The chemistry of these ligands has been extensively reviewed [57, 58]. In 
general, AR ligands were identified through in vitro binding or reporter gene assays. They 
are largely classified as agonists or antagonists based on their ability to activate or inhibit 
transcription of AR target genes. All of these ligands modulate AR function by binding to the 
LBP in the LBD. The receptor is able to accommodate many different ligands by modifying 




1.2.3.1.1. AR agonists 
The two most important endogenous androgens are testosterone and DHT (Figure 
3A). The functions of androgens were first described in 1889, when French physiologist and 
Professor of Medicine Charles Edward Brown-Sequard first identified androgen action 
through self-injections of testicular extracts. Subsequently, in 1935, Professor Ernst Laqueur 
and collaborators from the Netherlands characterized and named the active ingredient in the 
extract testosterone [60]. Another hallmark in the history of androgen biochemistry was the 
discovery that a fraction of testosterone is metabolized to the more potent androgen DHT in a 
reaction catalyzed by 5α–reductase [61, 62]. DHT differs from testosterone by the absence of 
a single double bond on ring A (Figure 3A) [13], which increases its affinity for the AR two-
fold and decreases the rate of dissociation five-fold relative to testosterone [63], differences 
that account for essential, DHT-specific functions.  
 
The first structure of the AR LBD was solved with the AR in complex with the potent 
synthetic androgen R1881 (metribolone) (Figure 3A) and shows the AR in an agonist 
conformation with the ligand inside of the LBP formed by H3, H5 and H11 (PDB: 1E3G) 
(Figure 2D and 3B) [54]. Later, structures of the AR LBD complexed with its physiological 
agonists DHT (PDB: 1I37 or 2AMA) and testosterone (PDB: 2AM9) were solved (Figure 
3B) [64, 65]. These three AR LBD agonist structures have very similar overall 
conformations, revealed key ligand and receptor interaction sites, and helped to define the 
general structural requirements for the binding of ligands in the LBP. R1881, DHT, and 
testosterone have 18, 16, and 15 contact points, respectively, with the LBD at a van der 
Waals distance cutoff of 4 Å (Figure 3C). These residues are hydrophobic and interact 
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mainly with the steroid scaffold. The remaining amino acids are polar and form hydrogen 
bonds with the polar atoms of the ligand. Notably, there are four hydrogen bonds formed 
between the LBD and DHT/Testosterone/R1881. As shown in Fig. 3C, the keto group of ring 
A interacts with the side chains of amino acids Q711 and R752, whereas the hydroxyl group 
at the 17β-position hydrogen-bonds with the side chains of N705 and T877. The position of 
the side chains is perfectly conserved in all three ligands studied, suggesting that this 
interaction is particularly important for the binding of androgens. This may explain why the 
AR binds androgens with a strong affinity in the low nanomolar range. A gross comparison 
of the AR complexed with DHT and testosterone showed no major differences in the protein 
structure able to account for the differences in DHT and testosterone physiological activity. 
A close analysis of the structure of DHT and testosterone showed that the presence of an 
unsaturated bond between C4-C5 in testosterone results in a change in the geometry of the A-
ring, which changes the orientation of the ketone group at C3. This altered geometry changes 
the distance and angle of the hydrogen bond with residue R752 to favor the AR LBD 
interaction with DHT over that with testosterone [65].  
 
In an unbound state, the AR complexes with heat-shock, chaperone and co-chaperone 
proteins (such as HSP90, HSP70 and p23), which helps to maintain the apo state of the AR in 
a state competent to bind ligand (Figure 1A) [66]. However, in an agonist-bound state such 
as was seen in the crystal structure of DHT-bound AR (PDB: 1I37 or 2AMA), H12 was held 
near H3 and H4 (Figure 3D). This conformational change in the LBD has also been seen in 
other nuclear receptors, such as the retinoic acid receptor (RARγ) bound to all-trans retinoic 
acid (PDB: 2LBD) [67], thyroid hormone receptor (TRα) bound to 3,5,3'-triiodothyronine 
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(PDB: 3GWS) [68, 69] and peroxisome proliferator-activated receptor-α (PPARα) bound to 
the agonist ligand GW409544 (PDB: 1K7L) [70]. Hormone binding creates an ‘active’ 
conformation of the receptor that primes the receptor for coactivator binding to an AF2 
region comprised of H3, H4 and H12. Many nuclear receptors retain full ligand-dependent 
transcriptional activity by binding to coactivators containing short leucine-rich LxxLL motifs 
(where “x” can be any amino acid) known as nuclear receptor (NR) boxes [71]. Binding to 
coactivators and association with histone acetyl transferase coactivator complexes such as 
p300/CBP results in potent histone acetyl transferase activity [7, 72]. We and others have 
shown that the AR can bind with high affinity to some LxxLL motifs in p160 coactivators 
[73, 74]. However, phage display demonstrates that the AR has a strong preference for the 
phenylalanine-rich motif FxxLF, or motifs with phenylalanine or tryptophan at positions +1, 
+5 or both [75]. Mutational changes of the +4 and +5 residues abolished the interaction of the 
motifs with the AR, which further confirms the importance of intact +1, +4, and +5 
hydrophobic amino acids in the motif [76]. Structural studies have revealed that this strong 
preference is due to geometrical and conformational constraints that occur between a cofactor 
and a cofactor binding site on the LBD (PDB: 1T7R) [75, 77]. The side chains of coactivator 
aromatic residues F+1, L+4 and F+5 insert into the hydrophobic cofactor binding groove on 
the LBD surface formed by helices 3, 4 and 12 (Figure 3D, left and middle panel). Amino 
acid side chains in the coregulator recognition site of the LBD can rearrange upon motif 
binding, a phenomenon known as the induced fit mechanism [77]. The charged amino acids 
lysine in H3 (K720 in AR) and glutamate in H12 (E897 in AR) are highly conserved among 
different nuclear receptors (Figure 3D, right panel).  These residues are located at the end of 
the groove and electrostatically interact with the coactivator backbone, thus forming a 
17	  
	  
“charge clamp” between the amide nitrogen of F+1 and E897 and the carbonyl group of F+5 
and K720 (Figure 3D, middle panel). This type of electrostatic interaction adds specificity to 
the recognition of different coregulators [73]. The AF2 domain is important not only for 
forming the coregulator binding site; it also mediates the preferred N/C interaction mentioned 
earlier [40, 78]. In recent years, an additional surface cleft called BF3 (binding function 3) 
was found to allosterically regulate AF2 coactivator binding (Figure 3E) [79-81]. This was a 
surprising finding to the group, as they initially set out to identify compounds that bound the 
AF2 pocket through a high-throughput screen. Interestingly, this site, localized by x-ray 
crystallography, reveals that compounds such as 3,3’,5-triiodothyroacetic acid (TRIAC) 
(PDB: 2PIT) and flufenamic acid (PDB: 2PIX) bind to a hydrophobic cleft at the junction of 
H1, the H3-H4 loop, and H9 (Figure 3E). The LBD has another important feature: the 
regulation of AR nuclear export. The AR is exported to the cytoplasm upon ligand 
withdrawal [82]. The presence of a nuclear export signal (NES) (residues 742-817) (Figure 
1B) in the surrounding vicinity of the bound ligand can sense ligand withdrawal and thus 






Figure 3. Structural basis of AR agonism. A. Chemical structures of testosterone, 
dihydrotestosterone and R1881. B. Structural overlay of the AR LBD complexed with 
testosterone (PDB: 2AM9, orange), dihydrotestosterone (PDB: 1I37, green), and R1881 
(PDB: 1E3G, purple). C. Comparison of the binding of R1881, testosterone, and 
dihydrotestosterone in the AR ligand-binding pocket.  AR LBD residues within a distance of 
4 Å are shown. Key residues (N705, Q711, R752 and T877) that form hydrogen bonds with 
ligands are labeled and shown in stick presentation. Hydrogen bonds are indicated by dotted 
lines. D. Structure of the AR LBD (purple) in complex with an FxxLF motif-containing 
peptide (yellow) (Left panel). The middle panel shows the interface between the AR LBD 
and the FxxLF motif. Hydrogen bonds are indicated by dotted lines with key residues 
labeled. A surface view of the motif-binding hydrophobic pocket is shown. A sequence 
alignment of helices H3 and H12 of the androgen receptor (AR), estrogen receptor (ER), 
progesterone receptor (PR), mineralocorticoid receptor (MR) and glucocorticoid receptor 
(GR) was performed using ClustalW. E. Structure of the AR LBD complexed with 3,3’,5-
triiodothyroacetic acid (TRIAC) (PDB: 2PIT). Left: cartoon representation; right: surface 




Antiandrogens are AR ligands that antagonize the actions of androgens by competing 
for AR binding sites. Antiandrogens can be both steroidal and non-steroidal. Steroidal 
antiandrogens include cyproterone acetate, oxendolone, and spironolactone (Figure 4A). 
Steroidal antiandrogens have limited clinical applications due to their undesired side effects; 
this then led to the development of nonsteroidal antiandrogens. Toluidide derivatives such as 
flutamide, bicalutamide and nilutamide (Figure 4B) are pure antiandrogens without 
androgenic properties; this lack of androgenic properties makes them suitable for use in the 
treatment of prostate cancer [57].  
 
Thus far, only the binding mechanism of agonists to the AR has been described (see 
section 1.2.3.1.1.), and the structural mechanism for antagonism of the AR remains unclear. 
In contrast to the AR, the structural basis of antagonism has been elucidated for other nuclear 
receptors, e.g., from the structures of 4-hydroxyltamoxifen (4-OHT) bound to the ER [84], 
RU-486 bound to the GR [84, 85] and the antagonist GW6471 bound to PPAR-α [86]. From 
these structures, we have learned that H12 becomes displaced over the coactivator binding 
pocket, which in turn prevents coactivator binding (Figure 4C). In the case of the ER, the size 
and structure of 4-OHT prevent the molecule from being completely confined in the cavity, 
leaving its bulky side chain protruding against H12 and preventing H12 from adopting a 
position essential for coactivator interaction. The schematic diagram in Figure 4C shows the 
different positions of NR AF2 in both the agonist-bound and antagonist-based states [87]. In 
the structure of PPAR-α bound to the antagonist GW6471, H12 rotates clockwise toward H3 
and blocks the coactivator binding site (Figure 4C and 4D). In addition to blocking 
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coactivator binding, H12 repositioning allows the recruitment of corepressors such as nuclear 
receptor co-repressor 1 (NCoR) and silencing mediator of retinoic acid and thyroid hormone 
receptor (SMRT) (PDB: 1KKQ) (Figure 4D) [86].  
 
It is unclear whether the mode of antagonism observed in other nuclear receptors is 
relevant to the AR as the structure of the antagonist form of the AR LBD has not been 
solved. However, functional studies do suggest that the H12 displacement model is likely 
applicable to the AR [88, 89]. It is believed that bicalutamide binding blocks AF2 function. 
Computer modeling suggests that the displacement of H12 by bicalutamide would not be as 
dramatic as those seen for the ER. The model depicts a shift of the N terminus of helix 12 
upwards and away from H3 and H4, which is believed to be sufficient for the distortion of 
AF2-coactivator binding (Figure 4E) [89]. Antagonist-induced conformational changes were 
analyzed using limited trypsinization, demonstrating that the binding of agonists and 
antagonists result in different conformational changes [90]. This modulation of protein 
surface topology was proposed to enable the recruitment of a different repertoire of 
regulators. It was shown that antagonists induce recruitment of the corepressors NCoR and 
SMRT [7, 88, 91-93]. In the absence of conflicting evidence, the AF2 displacement model 
holds as the mechanism for AR antagonism.  However, the precise mechanism remains 
unclear, and a crystal structure of the AR LBD in the antagonist-bound conformation would 
be required to provide a better basis for the structure-based design of AR antagonists for the 






Figure 4. Structural model of AR antagonism. A. Chemical structure of the steroidal 
antiandrogens cyproterone acetate, oxendolone and spironolactone. B. Chemical structure of 
the non-steroidal antiandrogens flutamide, bicalutamide and nilutamide. C. Nuclear receptor 
H12 helices can adopt different conformations. In an agonist state, the H12 of DHT-bound 
AR (PDB: 1I37 or 2AMA) is held near H3, H4 and H11, which form a groove for coactivator 
binding. In an antagonist state, H12 rotates clockwise toward H3 and blocks the coactivator 
binding site. D. Structure of the PPARα LBD complexed with SRC-1 coactivator peptide 
(H12 in agonist conformation) and with the SMRT corepressor peptide (H12 in antagonist 
conformation). E. Computer model of antagonist-bound AR shows the predicted 




1.2.4. Modulation of androgen receptor through proteasome-dependent degradation  
Protein degradation is required for the elimination of misfolded or unfolded proteins 
and also for the maintenance of the AR cellular function. The ubiquitin-proteasome system is 
emerging as an important regulator in controlling the magnitude and the duration of the 
steroid hormone responses [94, 95]. Ligand-dependent and proteasome-mediated degradation 
has been demonstrated in the ER, PR and GR. On the contrary, DHT does not promote 
degradation of the AR. Instead, androgens have been shown to increase the AR protein levels 
in LNCaP cells [96]. The half-life of the AR in LNCaP cells is approximately three hours in 
the absence of androgens and ten hours in the presence of 10 nM of DHT. In the ligand-
independent subline of LNCaP, C4-2, AR has a half-life of seven hours in the absence of 
androgens [97]. Although the AR degradation is not ligand-dependent, Sheflin L et al, 
showed that the degradation of the AR is proteasome-dependent. They reported that MG132, 
a specific proteasome inhibitor, has increased the AR protein level in LNCaP, HepG2 and 
PC-3 cells [98, 99].   
 
The ubiquitin-proteasome system consist of a series of enzymes (ubiquitin-activating 
(E1), -conjugating (E2) and –ligase (E3) enzymes). Ubiquitin is a small 76 amino acid 
protein that will be covalently linked to target proteins and this process is repeated to 
generate a poly ubiquitin chain [100]. The AR contain a conserved PEST domain, located in 
the hinge region of the AR shown to target proteins for ubiquitination and consequent 
degradation [98]. The polyubiquitin chain is then recognized by the 26S proteasome 
complex. The mammalian 26S proteasome is a ATP-dependent-multi-subunit protein 
degradation complex composed of a 20S proteolytic core particle and a 19S regulatory 
25	  
	  
particle. This protein degradation complex will degrade proteins into small peptides with 
length of 3 to 24 amino acids [94]. 
 
1.2.4.1. Aryl hydrocarbon receptor and degradation of androgen receptor 
Ubiquitin attachment to a target protein is a three step reaction; 1) ubiquitin is first 
activated by the E1 activating enzyme in an ATP-fueled reaction. 2) the activated ubiquitin is 
transferred onto the E2 conjugating enzyme, and lastly, the E3 ligase transfers ubiquitin from 
E2 to the target protein for degradation [101]. E3 ligases are key players to determining the 
specificity of substrate recognition. E3 ligases, of which there are possibly hundreds of them, 
can be broadly divided into two families: the Homologous to the E6-AP C-Terminus (HECT) 
domain E3s, and the Really Interesting New Gene (RING)-finger domain E3s. Ligases 
belonging to both families were demonstrated to interact with the AR [102]. Mdm2 is a 
RING finger that contains the E3 ligase, which plays an important role in AR ubiquitination 
and degradation. Phosphorylation of the AR by AKT/PKB (protein kinase B) promotes 
Mdm2 ubiquitination of the AR [103]. More recently, it was reported that the Aryl-
hydrocarbon receptor (AhR) regulates the AR by acting as an E3 ubiquitin ligase [104]. Aryl 
hydrocarbon receptor is a cytosolic ligand-activated transcription factor that belongs to the 
basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family. AhR has been studied largely for 
its role in xenobiotic-induced toxicity and carcinogenesis [105]. AhR plays various 
physiological role in the reproductive and immune systems. This receptor when in its 
unliganded state, binds to HSP90. Ligand binding leads to a conformational change followed 
by translocation of AhR complex into the nucleus, where it regulates the gene expression of 
target genes, such as CYP1A1 and CYP1A2. Cross-talk between the AhR and AR was first 
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identified by Morrow et al, where in the presence of AhR agonist 2,3,7,8-
tetrachlorodibenzodioxin (TCDD), there was a decrease in the AR protein levels that results 
in a growth inhibitory effect on LNCaP cells [106]. The mechanism of the AR degradation 
by AhR was subsequently revealed by Ohtake et al [104], where in the presence of its ligand, 
AhR assembles into a ubiquitin ligase complex (CUL4LBAhR) to promote the AR 
proteolysis. 
 
1.3. AR and disorders 
Although the AR is involved in diverse activities, its primary functions are related to 
male physiology, such as sex differentiation and sex-specific pathology [107]. Defects in the 
AR gene can prevent the normal development of both internal and external male structures in 
46,XY individuals and result in androgen insensitivity syndrome, which is the partial or 
complete inability of cells to respond to androgens [13, 108, 109]. Defects in the AR gene 
can be caused by four types of mutations: (i) Single point mutations resulting in substitutions 
or premature stop codons, (ii) nucleotide insertions and deletions resulting in frameshifts, (iii) 
complete or partial deletion of the gene, or (iv) intronic mutations that affect AR RNA 
splicing [110]. Currently, 1029 distinct mutations have been identified in the human AR gene 
and are distributed predominantly over the AR DBD- and LBD-coding regions. These 
mutations are well documented in the Androgen Receptor Gene Mutations Database World 
Wide Web Server at the Lady Davis Institute for Medical Research, available at 
http://androgendb.mcgill.ca [111]. Several investigations have associated the polymorphic 
polyglutamine repeats in the NTD with Kennedy’s Disease, also known as spinobulbar 
muscular atrophy, a progressive neurodegenerative condition [112-114]. There are an 
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increasing number of studies relating the action of the AR to breast [115], larynx [116], liver 
[117] and testicular cancers [118]. 
 
1.3.1. AR and prostate cancer  
AR activity is intimately linked to prostate cancer, which is by far the most 
commonly diagnosed cancer among American men and the second leading cause of cancer 
deaths [119, 120]. In 2010, direct medical costs for prostate cancer were projected to reach 
$12 billion and are expected to further increase by 2020 [121]. Of the 1029 mutations found 
in gene that encodes the AR, 159 mutations predispose males to prostate cancer [111]. In 
addition, previous work has suggested that the length of the repeats in the NTD influences 
prostate cancer risk in men [23, 122, 123]. A meta-analysis of 19 studies including 
Caucasian, African-American and Asian subjects predicted an increased risk of prostate 
cancer in men with shorter (≤21) CAG repeats. However, a Swedish study suggests that men 
with shorter AR CAG lengths (e.g., ≤22 repeats) are at a greater risk of developing prostate 
cancer. Other studies found no association between the AR CAG repeat length and prostate 
cancer risk [124]. Although evidence that mutations in the AR predispose men to prostate 
cancer is undisputed, AR NTD CAG repeat length association with prostate cancer risk thus 
remains controversial.  
 
Prostate cancer cells, similar to normal prostate cells, require androgens to grow and 
survive. Growth of prostate cancer depends on the ratio of the rate of cell proliferation to the 
rate of cell death [125]. In prostate cancer, the rate of proliferation is higher than that of 
death, resulting in continuous net growth. Androgens and the AR are the main regulators of 
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this ratio. More than 70 years ago, Charles Huggins demonstrated that androgen deprivation 
by orchiectomy (removal of the testes) caused regression of prostate cancer [126, 127]. 
Increased serum levels of the important biomarker PSA suggest that AR activity is elevated 
in prostate cancer patients. According to the American Cancer Society, a PSA level above 4 
ng/mL has been recognized to be abnormal, and these patients are advised to undergo a 
biopsy [120, 128].  
 
The initiation of prostate cancer can in many cases be attributed to the activation of 
distinct growth-promoting pathways. One prominent example is the androgen-dependent 
upregulation of members of the E-twenty-six (ETS) family of transcription factors by gene 
fusions between the AR-regulated TMPRSS2 gene promoter and the coding region of the 
ETS family members erythroblast transformation-specific (ERG) and ETS variant 1 (ETV1), 
which have been estimated to occur in ~50% of prostate tumors [129-131]. These fusions 
confer androgen responsiveness to ETS transcription factors, which leads to cell-cycle 
progression. Interestingly, the induction of this fusion is itself dependent on the DHT/AR-
stimulated recruitment of three DNA-directed enzymes, activation-induced cytidine 
deaminase (AID), LINE-1 repeat-encoded ORF2 endonuclease, and topoisomerase II beta 
(TOP2B), that trigger chromosomal translocation [132, 133]. Other signaling pathways 
shown to be involved in prostate cancer initiation and progression include the PI3K and 
RAS/RAF pathways; dysregulation of these pathways in both early and late stage prostate 
cancer was implicated through genomic profiling [134]. In this study, analysis of the AR 
signaling pathway revealed a greater alteration compared with the other pathways, indicating 
that the AR is still the “master regulator” of prostate cancer.   
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AR pathway perturbation is the mechanistic rationale for the use of androgen suppression 
methods to treat prostate cancer. Initial treatment includes androgen suppression via 
castration through surgical (orchiectomy) or chemical (gonadotropin-releasing hormone 
(GnRH) analogues such as leuprolide and goserelin) means [135]. GnRH agonists desensitize 
the GnRH receptor by interrupting its physiological intermittent stimulation, whereas the 
GnRH antagonist degarelix blocks GnRH stimulation directly [136]. Patients are then placed 
on androgen deprivation therapy, which is usually combined with leuprolide for total 
androgen blockade [137, 138]. Deprivation is typically achieved by oral treatment with 
nonsteroidal antiandrogens, such as flutamide (Figure 3A), which was approved for the 
treatment of prostate cancer in 1989, and the newer, structurally related compounds 
bicalutamide and nilutamide (Figure 3A). 
 
1.3.2. AR and castrate resistant prostate cancer (CRPC) 
Patients on androgen deprivation therapy remain in long-term remission of the 
disease. However, the development of a castration-resistant disease is inevitable [139, 140]. 
This form of prostate cancer is lethal, and patients no longer respond to first-line androgen 
deprivation therapy. CRPC patients are usually treated with chemotherapy including the anti-
mitotic compound docetaxel, which has been demonstrated to confer a survival advantage 
[141, 142]. The mechanisms of castration resistance remain unclear but are thought to be 
diverse. For a comprehensive review of the mechanisms of CRPC development, the reader is 
referred to other excellent reviews [140, 143-146]. Briefly, there are four possible 
mechanisms of CRPC development: 1) Increased sensitivity of the AR to its agonists, 2) AR 
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mutations that render the receptor responsive to alternate, non-androgen ligands, 3) ligand-
independent AR activation, and 4) AR-independent mechanisms (Figure 5).  
 
Patients on androgen deprivation therapy have lower levels of circulating androgens, 
which initially curb prostate cancer cell proliferation; however, the opposite happens in 
CRPC patients, who have increased tumor cell proliferation. One of the underlying 
mechanisms of CRPC is an increase in the expression of AR in the cell. Koivisto et al. 
showed that 28% of androgen-independent tumors that developed after androgen deprivation 
therapy had increased AR expression due to AR gene amplification [147]. These results 
indicate that CRPC cells may not be strictly androgen independent, but rather, they become 
more sensitive due to a lowered threshold for androgens. Even under androgen deprivation 
therapy, androgen levels are sufficiently high to activate overexpressed AR, which is due to 
intratumoral in-situ synthesis [148] and residual synthesis in the adrenal gland [149], along 
with decreased levels of the androgen inactivating enzymes CYP3A4, CYP3A5 and CYP3A7 
in patient tissue samples [150].  
 
Another mechanism for the development of CRPC is ligand promiscuity, which 
results from AR gene mutations that cause amino acid substitutions in the LBD that decrease 
specificity and selectivity for ligands (e.g., T877A, L701H, W741L and F876L). These 
mutant AR proteins bind to other steroid hormones, such as estrogen, progesterone and 
glucocorticoids, which induce the activation of AR transcriptional activity resulting in 
prostate cancer growth [151]. In certain situations, AR mutations cause antagonists to induce 
an agonist conformation, resulting in AR activation rather than inhibition. Early examples 
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have been found in patients on flutamide treatment in combination with androgen blockade. 
Five of these 16 patients had the AR mutation T877A. Through luciferase assays, it was 
shown that the antagonist flutamide behaves like an agonist for these AR mutant proteins 
[152], and it was suggested that flutamide exerts a strong selective pressure for AR 
mutations.  
 
The third mechanism of CRPC development is AR activation through ligand-
independent mechanisms [153]. Studies have shown that tyrosine kinase receptor-activating 
ligands, such as insulin-like growth-factor-1 (IGF-1), keratinocyte growth factor (KGF), and 
epidermal growth factor (EGF), can activate the AR as a consequence of activating the 
downstream PI3K/AKT/mTOR pathway, thus creating an ‘outlaw receptor’. IGF-1 was able 
to cause AR activation, inducing a five-fold increase in PSA levels in LNCaP cells cultured 
in serum-free medium [154]. Activation of the AR complex can also occur via crosstalk with 
other signaling pathways, such as those mediated by the non-receptor tyrosine kinases Src 
and Ack1 [146, 155-158]. Recently, various groups have described AR activation by binding 
of long non-coding RNAs (e.g., PCGEM1 and PRNCR1) to the AR that can result in 
castration-resistant prostate cancer [159]. In addition, several AR variants that lack the LBD 
and act as negative regulators of the NTD have been described in CRPC. The AR NTD is 
constitutively active in the absence of the LBD and thus can promote androgen depletion-
resistant growth [145, 160]. 
 
The last pathway leading to CRPC bypasses AR signaling completely. It has been 
shown that castration therapy in mice triggers an inflammatory response released by the 
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dying cells. Proinflammatory factors produced by dying prostate cancer cells cause the 
infiltration of B and T cells. Infiltrating B cells produce lymphotoxin and factors that 
increase Stat 3 signaling, which is vital for promoting hormone-free survival of prostate 
cancer cells [161]. Similarly, upregulation of the anti-apoptotic protein Bcl-2 protects cancer 
cells from castration-induced apoptosis [162]. Very recently, CRPC tumors were found to 
upregulate the expression of GR, another member of the nuclear receptor family. GR was 
shown to drive the expression of a subset of AR target genes necessary for cancer cell 
survival [163]. The various pathways mentioned may operate simultaneously to enhance AR 
activity [164]. Most evidence suggests that ADT failure may not result from a loss of 
androgen signaling but rather from the acquisition of genetic changes that lead to aberrant 
activation of the AR and its signaling axis [111, 144, 165]. Thus, the AR remains a potential 
therapeutic target for prostate cancer therapy [37].  
 
In 2012, the second-generation AR antagonist enzalutamide (Figure 6) (MDV3100) 
was approved by the FDA for use in prostate cancer [166-168]. Enzalutamide is a more 
potent antagonist than bicalutamide because it binds to the AR ligand-binding pocket with 
higher affinity than first generation antagonists, such as bicalutamide, and also prevents the 
translocation of the receptor into the nucleus [169]. Recent studies have shown that 
abiraterone acetate (Zytiga), an inhibitor of the cytochrome P450 enzyme CYP17, impedes 
androgen synthesis and thus lowers the level of circulating ligand, improving overall survival 
in well-powered, randomized phase III studies [170, 171]. In addition, a series of new agents 
are in clinical development, including the AR antagonists ARN-509 [41] and EPI-001 that 
directly target the AR, as well as orteronel (TAK-700) [42] [43] and galeterone (TOK-001) 
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[44] that indirectly target the AR. Collectively, the development of enzalutamide, abiraterone 







Figure 5. Androgen and AR action in castration-resistant prostate cancer. Mechanism of 
castration-resistant prostate cancer. Several mechanisms promote the progression of 
castration-resistant prostate cancer: 1. AR overexpression coupled with continued tumor 
steroidogenesis. 2. Promiscuous binding and activation of mutant AR by alternative ligands, 
such as estrogen (E2), progesterone (P), glucocorticoids (C) and flutamide (F). 3. Ligand-
independent mechanisms of AR activation via crosstalk with Akt, HER2, and Ack1 kinases 
that phosphorylate the AR and via long non-coding RNAs (e.g., PCGEM1) that bind to the 
AR to stimulate transcription of AR target genes. 4. AR-independent pathways, in which 
cancer cell survival and growth are directed by Stat3 signaling or by upregulation of anti-
apoptotic Bcl-2. Glucocorticoid receptor (GR) was found to activate a similar set of AR 







1.4. Structural understanding of disease/drug resistance-related androgen receptor 
mutations through X-ray crystallography and structure modeling  
Because the AR remains the driving force in the progression of more aggressive 
castration-resistant prostate cancers [146], it is important to understand how each genetic 
aberration affects the pharmacology of the AR and its ligands. Through the use of X-ray 
crystallography and computer modeling, biochemical observations can be understood at the 
atomic level, which is expected to greatly aid the design of improved drugs to overcome 
current clinical problems.  
 
1.4.1. Structural basis of mutation-induced AR promiscuity 
1.4.1.1. DHT-bound AR LBD T877A  
The single point mutation T877A has been found in LNCaP cells and prostate cancer 
patients to confer abnormal binding characteristics to the AR. This mutation has been shown 
to cause a significant increase in the affinity of the AR for binding to estrogens and 
progesterone. In addition, this mutation also allows the AR to be activated by antiandrogens 
such as flutamide [152, 172]. To understand the structural basis of this abnormal binding 
characteristic, Sack et al. solved the crystal structure of the wild-type (WT) (PDB: 1I37) and 
T877A (PDB: 1I38) AR LBDs complexed with DHT [64]. A comparison of both structures 
revealed similar overall conformations. Interactions between DHT and both forms of the AR 
occur at almost identical points of contact, except at the mutated residue (Figure 7A). 
Interestingly, the introduction of the T877A mutation created additional space around the D-
ring of DHT. This increase in volume allows bulkier ligands to enter the pocket, and this may 
induce AR promiscuity for other hormones and analogs, such as estrogens and progesterone. 
36	  
	  
Conversely, the presence of T877 limits the pocket size and is thought to be important for 
ligand specificity. The concept that an increase in the LBP may increase ligand promiscuity 
was further supported by biochemical studies in which threonine was replaced by the larger 
amino acid aspartic acid, which prevented androgen binding, presumably by steric hindrance, 
making the mutant receptor unresponsive to androgen activation [173].    
 
1.4.1.2. 9α-fluorocortisol-bound AR LBD L701H/T877A 
Two mutations, L701H and T877A, were identified in the androgen-independent 
prostate tumor cell lines MDA 2a and 2b. The double mutation allows the AR to be activated 
in the absence of androgens. Both mutations are located in the LBD and strongly increase AR 
sensitivity to cortisol and cortisone, which in turn leads to the promotion of prostate cancer 
cell growth [174]. Not surprisingly, the double mutant also renders the receptor responsive to 
progesterone and estrogen due to the presence of the T877A mutation, most likely for the 
reason mentioned in the above section. However, the T877A mutation alone is insufficient to 
promote receptor binding and activation by cortisol. Matias et al. provided a structural basis 
for the glucocorticoid responsiveness of the AR LBD double-mutant L701H/T877A (Figure 
7B) [175]. The overall fold of the L701H/T877A double-mutant AR LBD complexed with 
9α-fluorocortisol (PDB: 1GS4) is similar to previous agonist structures. The main structural 
difference is the formation of a favorable hydrogen bonding network between the D- and C-
rings of 9α-fluorocortisol and A877, H701, and S778 of the mutant receptor. Specifically, 
hydrogen bonding between S778 and H701 correctly positioned the imidazole ring of H701 
to form a hydrogen bond with the hydroxyl group on the D-ring to form a hydrogen bond 
with H701, whereas A877 was able to form a close Van der Waals contact with the D-ring of 
37	  
	  
9α-fluorocortisol. In contrast, a threonine residue at position 877 would be extremely 
unfavorable for 9α-fluorocortisol binding, and the hydrophobic leucine at position 701 in the 
wild-type receptor would be unable to engage in the formation of this stabilizing hydrogen 
bond network. 
 
1.4.1.3. The V730M mutation alters coactivator selectivity 
V730M is a somatic mutation that was detected in an advanced-stage prostate 
carcinoma that resulted in an increase in AR activation by androgens [176]. The crystal 
structure of the wild-type AR illustrated the reason why the LxxLL motifs of typical NR 
coactivators fail to hydrogen bond with Glu897 of H12 and make fewer and less optimized 
hydrophobic contacts with the AF2 pocket compared with FxxLF-containing peptides, 
explaining the lower affinity of AF2 for the LXXLL-containing p160-type coactivators [75]. 
In contrast, cell-based reporter gene assays and in vitro binding assays showed that V730M 
increases LxxLL binding without affecting FxxLF binding, resulting in increased overall AR 
transcriptional activity [77]. In three-dimensional space, V730 is located near the coactivator 
binding site [77] and, along with M734 and I737 in the hydrophobic groove, allows the 
formation of a smoother and flatter surface that permits greater complementarity to FxxLF 
compared with the LxxLL motif (Figure 7C). A mutation of V730 to methionine would alter 
the interaction surface to become more favorable to binding to LxxLL motifs and thereby to 
the recruitment of LxxLL motif-containing coactivators, such as the SRC coactivators, which 
are commonly associated with the AR in recurrent prostate cancer [7, 177, 178].  
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1.4.2. Mutations alter drug antagonist properties 
1.4.2.1. Bicalutamide-bound AR LBD W741L 
The administration of antiandrogens is the standard approach to treat prostate cancer. 
Examples of first generation antiandrogens include bicalutamide, flutamide, and nilutamide, 
which inhibit androgen action by binding to the androgen receptor in a competitive fashion, 
i.e., as an antagonist. Unfortunately, these first-generation drugs demonstrated agonist 
properties in LNCaP cells, which overexpress the AR, a state that mimics castration-resistant 
prostate cancer. Hara et al. reported two LBD mutations, W741L and W741C, in LNCaP 
cells that appeared during bicalutamide treatment and caused the receptor to be activated by 
bicalutamide [179]. The structure of the AR LBD W741L bound to bicalutamide shed light 
on how the mutation imparts agonistic properties leading to bicalutamide resistance [180]. In 
the structure, bicalutamide adopts a bent conformation within the ligand-binding pocket 
(Figure 7D). Although hydrophobic interactions account for the majority of the contact 
points between bicalutamide and the AR LBD, hydrogen bonds form in two different 
regions. Similar to the previous structures of the AR bound to R1881 and DHT, the cyano 
group of the bicalutamide A ring forms hydrogen bonds with Q711 and R752. Additional 
hydrogen bonding was observed between the amide nitrogen and the chiral hydroxyl group 
of bicalutamide and amino acids L704 and N705. Unlike in the structures of R1881- and 
DHT-bound AR, T877 is not involved in hydrogen bonding (Figure 7D), which may explain 
the lower binding affinity of bicalutamide compared with R1881 or DHT. In the presence of 
the W741L mutation, the bulkier side chain of tryptophan is replaced by the smaller side 
chain of leucine. This provides more space to accommodate the B-ring of bicalutamide, 
allowing the AR to maintain a similar fold as that seen in other agonist-bound structures and 
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thus favoring the formation of an active state of AF2. In other words, this increase in space in 
the LBP would allow bicalutamide to bind without displacing H12, which is the basis for its 
antagonist activity. 
 
1.4.2.2. MDV3100 and AR LBD F876L 
The recent FDA approval of enzalutamide (Figure 6) and the development of ARN-
509 reiterate the importance of targeting AR signaling for CRPC treatment [167, 169]. 
Despite the success of enzalutamide at causing a significant drop in the serum PSA levels of 
patients, responses to enzalutamide are often short-lived. Some causes of resistance to 
enzalutamide have been identified [181, 182]. Through a reporter-based mutagenesis screen, 
Balbas et al. identified the AR mutation F876L.  In contrast to wild-type AR, enzalutamide 
functions as an agonist for AR F876L and causes the mutant receptor to bind enzalutamide 
six times more effectively than wild-type receptor [183]. To understand the effect of the 
F876L mutation, the group also mutated F876 to a bulkier residue, tyrosine, or to another 
aliphatic amino acid, isoleucine.  Only the F876I mutation caused enzalutamide to behave as 
an agonist, similar to F876L, indicating that resistance is due to a clear structural change in 
the drug-receptor complex. As the structure of enzalutamide-bound AR has not been 
reported, the Sawyer group modeled the AR-enzalutamide complex through ligand docking 
and molecular dynamics simulations. Docking suggested that enzalutamide interacts with the 
wild-type AR differently than with bicalutamide. As seen in Figure 5D, the B-ring of 
bicalutamide makes contact with H12. However, enzalutamide does not interact with helix 
12; instead, its C-ring interacts with the C terminus of helix 11 and the loop region between 
helix 11 and helix 12. It was proposed that this accommodation allows enzalutamide to 
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directly contact F876, resulting in a conformational rearrangement in helix 11 that prevents 
helix 12 from adopting the agonist conformation required for coactivator binding. In contrast, 
in the presence of the F876L mutation, leucine lacks the favorable contact with enzalutamide 
that is predicted to be necessary for helix 12 displacement. Hence, helix 12 is thought to 













Figure 7. Structural understanding of disease/drug resistance-related androgen 
receptor mutations. A. Structural comparison of wild-type (PDB: 1I37) and mutant T877A 
(PDB:1I38) AR LBDs in complex with dihydrotestosterone. Key residues involved in 
hydrogen bonding have been highlighted, with hydrogen bonds indicated by black dotted 
lines. B. Structure of the AR LBD double mutant L701H/T877A complexed with 9α-
fluorocortisol (PDB: 1GS4). C. Structural overlay of androgen receptor complexed with 
FxxLF (PDB: 1XOW) and LxxLL (PDB: 1T7F) motif-containing peptides. Residues V730, 
M734 and I737 are involved in forming hydrophobic contacts with coactivator peptides. 
Residue V730 was mutated to M730 to demonstrate an enhanced binding of LxxLL peptides. 
D. Structure of AR LBD W741L complexed with bicalutamide (PDB: 1Z95). Residues L704, 
N705, Q711 and R752 form hydrogen bonds with bicalutamide (indicated by dotted lines). 
Also shown is the wild-type W741 residue (white) to illustrate a possible steric clash between 
tryptophan and the B-ring of bicalutamide.  
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1.5. Rational drug discovery in progress 
A growing amount of evidence suggests that mutations in the AR-encoding gene 
occur spontaneously in prostate cancer and eventually result in the relapse of patients. As a 
consequence, the effects of drugs change, and patients are no longer responsive to treatment. 
These gain-of-function mutations present a scientific challenge to pharmacologically 
overcome the mechanisms of drug resistance and further highlight the importance of 
identifying advanced compounds to inhibit AR activity. Rational drug design, which is the 
application of a structure-function relationship, is now widely used in modern medicinal 
chemistry for developing exquisitely selective ligands. 
 
Can the available structural information on AR-ligand interactions based on x-ray 
crystallography and modeling be exploited for the rational design of next-generation 
antiandrogens to overcome problems with antiandrogen resistance? Available structures of 
the wild-type and mutant AR in complex with ligands reveal a clear explanation for how 
changes in a single residue can result in dramatic changes in ligand-binding properties and 
pinpoint the key determinants of receptor-ligand specificity and affinity. This information 
will greatly facilitate the development of new antagonists for the treatment of prostate cancer. 
Hence, this section will provide an overview of the development of new antiandrogens. 
 
1.5.1. Targeting the NTD 
Hypothetically, there are numerous regulatory sites that can be therapeutically 
exploited. As discussed earlier in this review, various functional domains, such as the NTD, 
DBD and LBD, can be targeted by small molecules. Targeting the intrinsically unstructured 
44	  
	  
NTD remains a challenge. Nevertheless, it is an attractive target for developing novel 
therapeutics, especially in light of increasing reports indicating that constitutively active AR 
splice variants that lack the LBD are found in prostate cancer patients. A number of NTD 
inhibitors have been reported in the literature, with decoy proteins providing the first proof-
of-concept evidence that targeting the NTD is a viable method to pre-clinically control the 
growth of CRPC [184]. NTD peptide (amino acids 1-558) was overexpressed to 
competitively block binding of interacting proteins or the N/C interaction. In another study, 
Anderson et al. reported the identification and characterization of the small molecule EPI-
001, which was isolated from the marine sponge Geodia lindgreni and targets the NTD-AF1 
domain. This compound also reduces the interaction between the NTD and the known AF1-
interacting coactivator CBP. EPI-001 was effective in mice bearing LNCaP xenografts, with 
no apparent toxicity detected. Thus far, this is the best characterized compound shown to 
effectively target the AR NTD for treatment of CRPC [185]. Recently, this group has 
continued to design new EPI-001 analogs that target the NTD and are currently under clinical 
development for human study [186].  More high-throughput screens have been used to 
identify new classes of compounds, such as the glycerol ethers niphatenones isolated from 
the sponge Niphates digitalis, which are proposed to covalently bind the AF1 and may serve 
as lead compounds for further drug development [187]. 
 
1.5.2. Targeting the DBD 
Fewer strategies targeting the DBD have been explored to date. In early work, a 
hairpin pyrrole-imidazole polyamide was designed to target the ARE to disrupt AR DBD 
binding and was effective at inhibiting androgen-induced PSA expression in LNCaP cells 
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[188]. Building on this work, affinity and specificity were further improved by creating a 
cyclic polyamide with a greater effect on decreasing PSA mRNA levels [189]. Although this 
was an ingenious approach, allosterically affecting the conformation of double-stranded 
DNA to prevent the AR DBD from binding has limited clinical applicability. This is because 
each polyamide can only target a subset of AR-dependent genes, instead of simultaneously 
targeting all AR-dependent genes important for disease progression. To overcome this 
shortcoming, a recent report described a high-throughput screen to target the AR protein 
rather than the DNA to reduce AR binding to the promoter and enhancer regions of PSA and 
TMPRSS2. Of ~160,000 molecules, the authors identified 1-(3-(2-chlorophenoxy)propyl)-
1H-indole-3carbonitrile (CPIC) as a compound that was able to reduce AR-specific DNA 
binding, although it remains unclear whether this compound works directly by binding to the 
DBD [190]. Given that the structure of the AR DBD has been solved, one might have 
expected the development of further DBD-targeted drugs. However, this has not been the 
case. One factor that may be limiting progress in this area of research lies in limited 
specificity, given that the DBD has high sequence homology among all members of the 
nuclear receptor family. This issue needs to be addressed before DBD-targeted drugs will 
enter the market. 
 
1.5.3. Targeting the LBD 
1.5.3.1. Targeting AF2 and BF3 
It is generally accepted that AR activation requires the formation of a functional AF2 
region for interactions with both cofactors and N/C. This makes the AR AF-2 surface an 
attractive target to modulate AR activity. Compounds that bind the AF2 would hypothetically 
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prevent intramolecular association between the AR LBD and NTD and interactions of the 
LBD with coregulators. Selective peptide inhibitors have been developed for ligand-bound 
ER and TR [191]. A similar approach could be adopted for the AR.  Hydrophobicity, size, 
and complementarity all substantially contribute to differential binding affinity and to the 
selective high-affinity binding of the AR AF2 to phenylalanines at the +1 and +5 positions in 
coactivator recognition helices. Hence, inhibitors that are designed to bind to the 
hydrophobic groove at the +1 or +5 sites to disrupt coactivator interaction may provide 
promising leads [73]. The feasibility of targeting AR in its coactivator binding pocket was 
demonstrated using peptide antagonists [192]. Phenylalanine-rich peptide antagonists were 
able to inhibit AR gene reporter activation without affecting PR-mediated activation, 
demonstrating some level of specificity for the androgen receptor. However, as different 
nuclear receptors have evolved to bind hydrophobic LxxLL consensus motifs through similar 
binding mechanisms, it remains important that mimetics are designed in a way that conveys 
greater selectivity to the AR. Improving mimetics by including specific flanking sequences is 
expected to improve selectivity, as studies have shown that the sequences immediately 
flanking the consensus motif confer specificity in vivo [76, 193-196]. Further 
characterization of the unique requirements for androgen receptor-specific coactivator 
binding may be useful for the design of peptide antagonists. The effects of AR peptide 
antagonists have been evaluated in mammalian cell-based assays; however, none has been 
further evaluated in animal models, and thus, it remains unclear whether they will be 
effective in vivo. The use of peptide antagonists may be difficult as drug delivery of small 
peptides can be a rather challenging task to overcome. In place of peptide antagonists, 
Axerio-Cilies et al. employed methods of computer-aided drug discovery to discover small 
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molecule inhibitors of the AF2 using the ZINC database, which currently consists of ten 
million purchasable compounds in the market. Six lead compounds were found to inhibit AR 
transcriptional activity. These authors confirmed by X-ray crystallography that compound 5 
binds specifically to the AF2 site (PDB: 2YHD) [197].  
 
The same group adopted this method to identify inhibitors that target the BF3 [198]. 
Several X-ray structures (PDB: 2YLP, 2YLO, 4HLW) confirmed the presence of the BF3 
site and its importance in regulating the AF2. Both AF2 and BF3 inhibitors provide new 
therapeutic avenues that could potentially help overcome the gain-of-function mutations that 
are selected for in the presence of current antiandrogens. By targeting a different site on the 
AR, AF2 and BF3 inhibitors can be concurrently taken with antiandrogens to prolong time to 
cancer remission. 
 
1.5.3.2. Targeting the LBP 
Finally, drugs can be designed to bind to the ligand-binding pocket. Over the past 
decade, most research efforts have been devoted to the design of small molecules that target 
the LBP, which is well ordered in crystal structures. Current research is focused on designing 
AR inhibitors with high affinity and specificity. Antiandrogens that have a high enough 
binding affinity to sufficiently displace DHT from the ligand-binding pocket need to be 
designed. Based on the agonist-AR LBD complex structure, it is believed that favorable H 
bonding between the ligand and AR T877, N705, Q711 and R752 and a hydrophobicity 
within a proper range are critical for ligands to bind to the AR with high affinity. Computer 
modeling of the binding of AR antagonists such as flutamide, nilutamide and bicalutamide 
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also suggested that both polar and hydrophobic interactions are essential for proper binding 
to anchor those compounds into the pocket [199]. A structural comparison of the wild-type 
AR bound to DHT and the agonist-converted AR-bicalutamide complex demonstrated that 
the sites that bind the A and B rings of DHT are similar to the sites bound by bicalutamide. 
Only the C6, C7 and C8 atoms of the B ring and the C15 and C16 atoms in the D ring of 
DHT bind to locations not bound by bicalutamide [180]. Additional van der Waals 
interactions by these atoms are likely responsible for the much higher binding affinity of 
DHT. Hence, designing antiandrogens with increased bulk in this region may enhance 
binding affinity. Enzalutamide was developed by ligand-based drug design, which relied on 
the pharmacophores of known drugs, to bind and inhibit the AR with a much improved 
binding affinity (IC50 = 21 nM, compared with 160 nM for bicalutamide) [169]. Specifically, 
enzalutamide was developed by starting with the AR agonist RU59063 and systematically 
modifying its chemical groups while maintaining the steroid fold [169].  
 
Specificity is another key factor to consider in the design of antiandrogens. Although 
enzalutamide generally seems to be well tolerated in humans, there was a low incidence of 
adverse events where patients developed seizures [200]. This effect was postulated to be a 
result of inhibition of GABA-gated chloride channels, as shown in animal models [201]. 
Such off-target effects can be minimized or eliminated by ensuring tissue selectivity. Entry of 
selective steroid receptor antagonists into different target tissues would be a new avenue to 
explore to avoid neurological side effects. However, to date, structural features that are 
essential for achieving uptake selectivity have not been determined. Building on the success 
of enzalutamide, the Sawyer group developed the compound ARN-509 by maintaining the 
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strong affinity of enzalutamide while reducing its off-target effects. ARN-509 has greater 
efficacy compared with enzalutamide in laboratory animals and is currently undergoing 
phase I clinical trials [202, 203]. Notably, the levels of ARN-509 in the brain are lower than 
those of enzalutamide at therapeutic doses, and phase I clinical trials have demonstrated an 
excellent safety profile and efficacy at decreasing PSA levels for ARN-509. Although the 
mechanism of tissue specificity remains unclear, there is clearly a need for further research in 
this area.  
 
The search for new AR antagonists is ongoing. In the absence of a structure showing 
the AR in antagonist conformation, the use of computer modeling has provided an entry 
point for structure-based drug design [204]. Recent drug discovery strategies are based on 
two criteria: First, compound structures that are distinct from bicalutamide and enzalutamide 
to avoid cross-resistance and, second, compounds that retain antagonist properties even for 
known AR mutant proteins that adopt agonist conformations when bound to current AR 
antagonists (also known as pan-antagonists). Small-molecule in silico screens have identified 
molecules that fulfill both criteria. For example, the compound DIMN (6-13,4-dihydro-1H-
isoquinolin-2-yl)-N-(6-methylpyrindin-2yl)nicotinamide) has shown promising in vitro 
antagonistic activity [205]. Similarly, Shen et al. identified another series of structurally 
defined AR antagonists, chemotype A-F compounds that function in the micromolar range 
and remain antagonistic for AR T877A and AR W741C. Interestingly, these compounds also 
impair nuclear localization and enhance AR degradation, thus providing a multi-pronged 
approach that might overcome all new somatic mutations that arise during the course of the 
disease [206]. Other candidates, such as compound 3 from the NCI-3D database [207], 
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DIMN analogs termed 7AU and 7BB [208], and MEL-3 [209], all showed encouraging in 
vitro activities and need to be tested in animal models. 
 
In silico models of drug-AR LBD complexes have provided a path for rational drug 
design to overcome the effects of agonist-converting mutations and restore the clinical 
efficacy of currently used drugs. In the structure of AR LBD W741L complexed with 
bicalutamide, the 4-fluorophenyl sulfone group of bicalutamide is located between residues 
of H12 and the side chain of L741.  A tryptophan at position 741 would result in a steric 
clash that would block H12 from adopting its agonist conformation (Figure 5C). McGinkey 
and Koh predicted that creating derivatives of bicalutamide with an expanded aryl sulfone 
core would extend farther toward H12 and would thus interfere with H12 adopting an agonist 
conformation even in the presence of the L741 mutation [210]. They validated their model 
with the compound PLM1, which exhibited no agonist properties in both wild-type and 
mutant conditions. Likewise, the flutamide derivative SC333 was shown to retain 
antagonistic properties toward AR T877A [211]. Recently, the Sawyer group has shown that 
it is possible to use structural and modeling data to chemically design and guide 
modifications of the enzalutamide structure to restore antagonism in the presence of the 
F876L mutation [183]. In their model, position 4 of the enzalutamide B-ring comes into 
closer contact with H12 in AR F876L. They predicted that contact with H12 may help 
reposition the AF2 into an antagonist conformation. To test this hypothesis, they synthesized 
a series of analogs with bulkier and more complex B rings. Of those compounds, DR103, 
DR105 and DR106 were able to overcome the effect of the F876L mutation and retain 
antagonistic properties. Molecular docking simulations suggested that DR103 would be 
51	  
	  
capable of displacing the N-terminal residues of H12, thus imposing an antagonist-like 
conformation. Efforts from all groups not only led to the design of a new pan-antagonist but 
also helped to confirm the proposed model for AR antagonism as a result of the displacement 
of H12.  
 
1.6. Botanical compounds and prostate cancer 
Drugs of natural origin continue to be important for the treatment of many diseases 
worldwide. A survey has indicated that there are over 120 single-entity plant-derived drugs 
used in western medicine [212]. Examples of commercially successful plant-derived drugs 
include atropine, codeine, colchicine, paclitaxel and quinine [213]. These compounds are 
mainly alkaloids which are nitrogen-containing secondary metabolites in plants. Another 
major class of secondary metabolite is the flavonoids. Flavonoids and flavones are ubiquitous 
compounds in fruits, vegetables and legumes. Epidemiological studies indicate that 
consumption of flavonoids and flavones reduce the prevalence and incidence of prostate 
cancer [214-216]. Flavones such as quercetin, kaempferol and luteolin was shown to bring 
about growth retardation in PC-3 prostate cancer cells, while genistein, apigenin, and 
myricetin suppresses PC-3 proliferation by a lesser degree [217]. Fisetin a flavone found in 
apples has been reported to decrease the AR stability and inhibit prostate cancer growth in 
animal models [218].  
 
1.6.1. Botanical: Epimedium (Berberidaceae) genus 
Epimedium (Berberidaceae), also known as Horny Goat Weed or Yin Yang Huo, is a 
genus for approximately 52 species of herbaceous flowering plants. More than 15 species in 
this genus have long been used in Traditional Chinese Medicine. Among the many species, 
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Epimedium saggittatum, Epimedium koreanum, Epimedium pubescens, Epimedium 
brevicornum are widely distributed and commonly used in China [219]. In vitro and in vivo 
experiments have demonstrated that Epimedium plants have wide-reaching pharmacological 
activities. Epimedium was found to stimulate the proliferation of osteoblasts-like cells 
UMR106 [220]. In China, Epimedium has been widely used to treat osteoporosis in 
menopausal women. We have shown that Epimedium brevicornum has selective estrogen 
receptor modulator effect and may be useful as an alternative to hormone replacement 
therapy in menopausal women [221]. Another study has shown that Epimedium sagittatum 
has angiogenic effect [222]. Epimedium is rich in flavonoids and lignans [223]. HPLC 
profiles determined flavonoids (icariin, epimedin A, epimedin B, epimedin C, baohuoside I, 
icaritin, desmethylicaritin, luteolin) are major constituents in Epimedium extract. Although 
investigations of its relative systemic toxicity and safety evaluations have been lacking, 
capsules or tablets have been sold in the market in various doses, ranging from 250 to 500 
mg. In animal studies, no major side effects were discovered [219].    
 
1.6.2. Lead Compound – Icaritin 
One major component in Epimedium is icariin (molecular weight: 676). Icariin is 
extensively bio-transformed into icariside II (molecular weight: 514), and icaritin (C16H20O6, 
molecular weight: 368, Figure 8) by human intestinal bacteria as shown through in vitro 








Figure 8. Chemical structure of icaritin. 
 
Early studies from other labs and our lab have shown that icaritin demonstrates a 
biphasic effect in breast cancer cells [225, 226]. Icaritin stimulated the growth of breast 
cancer (MCF-7) cells at low concentrations but exerted an unexpected suppressive effect on 
estrogen-stimulated breast cancer cell proliferation and gene expression at higher 
concentration destabilizing ER alpha protein through the AhR. Icaritin also promotes 
osteoblast proliferation and reduces osteoclastic bone resorption suggesting that it should be 
considered a candidate drug for the treatment of bone loss [227-229]. The potent effect can 
be attributed to its preferred distribution to the bones. A group has shown through in vivo 
imaging technique in zebrafish larvae that icaritin elicits bone-specific distribution [230]. In 
vivo work in rats showed that icaritin ameliorates the progression of liver fibrosis in rats 
[231]. Icaritin also have neuroprotective function. Icaritin protected neuronal cells against 
apoptosis induced by amyloid beta through an ER mediated pathway [232]. Icaritin exhibited 
anti-leukemia effect [233]. Interestingly, Icaritin has a dose and time dependent inhibition of 
cell growth in AR-negative PC-3 cells. It was observed that PC-3 cells possessed a more 
differentiated, fibroblast-like phenotype. There was a G1 cell cycle arrest at 30 µM [234].  
54	  
	  
1.7. Aims and significance of study 
Prostate cancer is one of the leading causes of illness and death in men. The clinical 
progression of prostate cancer from androgen-responsive to castration-resistant form is 
highly related to functions of the AR. As such, AR is the most therapeutically relevant target 
for the treatment of prostate cancer. There are many drugs available in the market for prostate 
cancer. However, a growing amount of evidence suggests that mutations in the AR-encoding 
gene occurs spontaneously in prostate cancer and eventually results in the relapse of patients, 
as they are no longer responsive to treatment. Thus, there is an urgent need to review and 
develop improved treatment strategies to combat prostate cancer. 
 
Through this project, we hope to identify and develop effective inhibitors that can 
abolish the AR signaling to improve the clinical management of prostate cancer. In this 
project, icaritin will be used as the lead compound. Its effect was tested in vitro and in vivo to 
examine the molecular basis of icaritin’s action. We choose clinically relevant cell lines 
(LNCaP , C4-2, CWR22RV1 and VCaP) as in vitro models in this study. LNCaP cells are 
androgen-dependent and its proliferation is dependent on AR signaling [235]. Another cell 
line used in this study is the C4-2 subline, which was derived from LNCaP cells through 
interaction with stromal cells under androgen-depleted condition in castrate host [236]. These 
cells have acquired androgen independence characteristics. C4-2 has chromosomal markers 
similar to their parental LNCaP cells. In other words, both LNCaP and C4-2 have similar 
genetic background. CWR22RV1 is a castrate-resistant prostate cancer cell line that 
expresses mutant H874Y androgen receptors and variant C-terminal truncated AR-V7 [237].   
To mimic the conditions of high AR expression in CRPC, VCaP prostate cancer cell line was 
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chosen. VCaP cells have endogenous AR gene amplification that leads to an overexpression 
of AR [238]. The use of these cell lines would be useful models to study icaritin’s effect on 
prostate cancer from an androgen-sensitive (LNCaP) to the castrate-resistant (C4-2, 










Chapter 2: Materials and Methods 
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2.1. Chemical Reagents 
Icaritin (purity 98%) was provided by Shenogen Pharma (Beijing, China). 
Bicalutamide, dihydrotestosterone (DHT), 3-methylcholanthrene (3MC), cycloheximide 
(CHX) and MG132 (Sigma) were commercially obtained from Sigma. Stocks were dissolved 
in dimethyl sulfoxide (DMSO). 
 
2.2. Cell lines 
The human prostate cancer cell lines: LNCaP, CWR22RV1, VCaP and PC3, normal 
prostate cell lines: RWPE-1 and WPMY-1, human breast cancer cell line MCF-7, human 
cervical cancer cell line HeLa and monkey kidney CV-1 cell line were obtained from ATCC. 
The cell line C4-2 was obtained from ViroMed Laboratories (Minneapolis, MN) and LNCaP-
luciferase (LNCaP-luc) was a gift from Dr Patrick Ling, Queensland University of 
Technology. LNCaP-luc was derived from the parental cell line LNCaP, which was obtained 
from ATCC. The cell lines were last authenticated in January, 2013 by LGC Standards (UK) 
Cell Line Authentication service. STR profiling of the cell lines were done using 
PowerPlex® 16 HS 16 Loci Service and the loci profiles were matched against the profile 
provided by ATCC.  
 
The LNCaP, LNCaP-luc, C4-2, CWR22RV1 and PC3 were cultured in RPMI1640 
medium (Gibco) supplemented with 10% fetal bovine serum (FBS). The VCaP, WPMY-1 
and MCF-7 cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS. 
The RWPE-1 cells were cultured in keratinocyte serum-free medium (Gibco) and 
supplemented with 5 ng/mL human recombinant EGF and 0.05 mg/mL bovine pituitary 
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extract (Gibco). The HeLa/AR stably transfected with construct containing androgen receptor 
were propagated in EMEM media supplemented with 10% FBS. Cells were incubated at 37 
°C, 5% CO2 in humidified incubator. 
 
2.3. MTS Cell Viability Assay 
Both prostate cancer cells and normal prostate cells were incubated in phenol red-free 
medium supplemented with 5% charcoal-stripped FBS for two days. The cells were next 
incubated with media containing compounds for 48 hours. Cell viability was determined by 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS; Promega) assay. The relative luminescence units (RLUs) were measured using a 
fluorescence microplate reader (Tecan) at a wavelength of 490 nm. The percentage of cell 
viability was calculated as such: % viability = [RLUsample – RLU media without cells] / 
[RLU DHT-treated cells – RLU media without cells] x 100%. For the cell growth assay, cells 
were incubated with media containing compounds for 0, 1, 3 and 5 days. Cell viability was 
determined using the MTS assay. All the experiments were repeated thrice. 
 
2.4. DNA fragmentation assay by propidium iodide staining 
DNA content of cells was analysed using propidium iodide (PI) staining. Cells were 
harvested, collected and pelleted down by centrifugation at 2,000 rpm. After washing twice 
with ice-cold 1x PBS, cells were fixed with ice cold 70% (v/v) ethanol by vortexing while 
adding ethanol to prevent clumping. The cells in ethanol were incubated for at least 1 hour at 
-20 °C. The fixed cells were then pelleted by centrifugation at 2,500 rpm for 5 minutes at 4 
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°C, washed twice with ice-cold 1x PBS before being stained with 500 µl of PI/RNase (10 
µg/ml PI, 250 µg/ml RNaseA in 1x PBS) solution for 30 minutes at 37 °C. Stained cells were 
filtered through a 40 µm pore size filter. At least 10,000 events were analysed for DNA 
content with flow cytometry (CyAn ADP, Beckman Coulter) with the excitation set at 550 
nm and emission at 610 nm. Data collected were analysed with the Summit 4.3 software 
(Beckman Coulter). In a typical DNA analysis, the apoptotic population of cells is 




The human cancer cells LNCaP and C4-2 were cultured in 6-well tissue culture 
plates. Cells were treated with icaritin and bicalutamide for 48 hours. After which, the 
changes in cell morphology were recorded and photographed using inverted phase contrast 
optics (Nikon Instruments). 
 
2.6. Quantitative RT-PCR 
Total RNA was extracted using the QiaShredder Kit (Qiagen) for cell 
homogenization and the RNeasy kit (Qiagen) for RNA isolation. cDNA synthesis was carried 
out using the SuperScript III Reverse Transcriptase (Invitrogen) according to the protocol by 
manufacturer. Quantitative PCR was done in StepOne Real-Time PCR system (Applied 
Biosystems) using the Taqman Gene Expression Assays (Applied Biosystem). Quantitative 
PCR for each sample was run in triplicate and each reaction contains 1 uL of cDNA in a total 
volume of 20 µL. ΔCt for each gene was determined after normalization to GAPDH. The 
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following Taqman probes for qPCR were used: KLK3 (Hs00426859_g1), TMPRSS2 
(Hs01120965_m1), FKBP5 (Hs01561006_m1), KLK2 (Hs00428383_m1), NDRG1 
(Hs00608387_m1), NKX3-1 (Hs00171834_m1), GREB1 (Hs00536409_m1), AZGP1 
(Hs00426651_m1), HPGD (Hs00168359_m1), SLC43A1 (Hs00992327_m1), 18S rRNA 
(Hs99999901_s1), AR (Hs00907244_m1), and CYP1A1 (Hs00153120_m1) (Applied 
Biosystems). Primers used for AR-V7 qPCR were:  
Forward: 5’ CTACTCCGGACCTTACGGGGACATGCG 3’ 
Reverse: 5’ TGCCAACCCGGAATTTTTCTCCC 3’. 
The log2-transformed signals of gene expression were plotted by heat mapping using 
Treeview version 1.60. 
 
2.7. Radioactive Competition Binding Assay 
The relative binding affinities in cells of icaritin and bicalutamide to AR, relative to 
DHT, was determined using a competition assay in which increasing concentrations of cold 
competitor are added to cells co-incubated with 3H-DHT. HeLa/AR stable cells were grown 
in charcoal treated 10 % FBS-EMEM before radioactive treatment. 8 x 104/well of HeLa/AR 
cells were plated in 24-well plates. After overnight incubation, triplicate cell samples were 
incubated with 1 nM 3H-DHT and increasing concentrations of cold competitor (1 pM to 1 
µM). The cells were incubated with hot and cold ligand for 19 hours, then washed in PBS for 
three times after media was discarded. Subsequently, 200 µL of Mammalian Protein 
Extraction Reagent (M-PER) (Thermo Scientific) was added into each well, gently shaken on 
an orbital shaker at room temperature for 5 minutes. 160 µL of total cell lysate was mixed 
with 5 mL of liquid scintillating cocktail and 3H bound radioactivity was counted for 1 
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minute per vial using a Tri-Carb 3100TR liquid scintillation analyzer (Perkin Elmer) with 
blank controls. Proteins in the cell lysate were quantified using Bio-Rad Bradford protein 
assay (Bio-Rad). The data were obtained as Counts Per Minute (CPM), readings were 
averaged and converted to Disintegrations per minute (DPM) with a counter efficiency of 
63%. The specific uptake of 3H-DHT was determined and normalized according to total 
protein. Specific AR binding was expressed as average (dm/mg) along with SEM. These data 
was plotted against the logarithmic transformed concentration of the cold competitor to give 
sigmoidal displacement curves. The IC50 values were determined using a one-site model 
using Graphpad Prism Version 5.   
 
2.8. Mammalian two-hybrid assay 
CV1 cells were cotransfected with a pVP16-ARTAD (amino acids 1–565, 220 ng), a 
pMGAL4-ARLBD (amino acids 628–919, 220 ng), a pGL3-Gal4Luc reporter (500 ng) and a 
PRL-renilla reporter (10 ng) using Fugene HD (Promega) per well in a 12-well plate for 2 
days. Cells were next treated with DMSO, 10 µM of bicalutamide and 10 and 30 µM of 
icaritin in the presence or absence of 10 nM DHT for 24 hours. The dual luciferase reporter 
assay system (Promega) was employed to measure the luciferase activity. 
 
2.9. Confocal microscopy 
LNCaP cells were cultured in Lab-Tek chambered slides (Thermo Scientific) and 
androgen-starved by culturing in media containing 5% charcoal stripped serum for two days.  
Next, cells were treated with DMSO (vehicle), 30 µM BIC, and 30 µM ICT in the presence 
or absence of 10 nM DHT for 6 hours. Cells were then permeabilized with 0.1% Triton-X 
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100 (Biorad) for 20 minutes at room temperature, then fixed in 4% paraformaldehyde for 30 
minutes at 4 °C and stained with a FITC-AR antibody (sc-7305 FITC, Santa Cruz) for 180 
minutes at 37 °C followed by counterstaining with 100 ng/mL 4',6-Diamidino-2-
Phenylindole (DAPI, Life technologies) for 5 minutes in the dark at 37 °C. Fluorescent 
staining was recorded using an Olympus Fluoview FV1000 confocal microscope (Olympus, 
Japan). 
 
2.10. Luciferase Reporter Assay 
Stably transfected HeLa-AR-ARE4-Luc cells [239] and LNCaP cells were transiently 
transfected with ARE-Luc reporter gene using Fugene HD (Promega), and were treated with 
the vehicle and icaritin for 24 hours. The cells were collected, lysed and the luminescence 
was measured with Luciferase Assay System (Promega) in a GloMaxTM 20/20 
Luminometer (Promega). Transcriptional activity was expressed relative to vehicle control 
and values were presented as mean ± SEM of triplicates. 
 
2.11. Chromatin immunoprecipitation (ChIP) assay 
Androgen-depleted LNCaP and CWR22RV1 cells were treated with 10 µM MG132 
for 30 minutes before the addition of other agents. The cells were then treated for 2 hours 
with DMSO (vehicle), 30 µM icaritin, 30 µM bicalutamide and DHT (10 nM for LNCaP and 
1 nM for CWR22RV1) alone or in combinations. The cells were cross-linked with 1% 
formaldehyde for 10 minutes at room temperature. The nuclei were isolated and sonicated on 
ice to break the chromatin DNA to an average length of 300-500 bp. Soluble chromatin was 
used in immunoprecipitation with AR antibody (sc-816, Santa Cruz). The immune 
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complexes were absorbed with protein G magnetic beads. After reversing the cross-links and 
digestion by proteinase K, immunoprecipitated DNA was quantified by qPCR using specific 
primers as below. The input control was applied to normalize each treated group. 
 
Primers for CHIP 












2.12. Extraction of protein samples and western blotting 
Protein extracts were extracted using RIPA Reagent (Thermo Scientific). Protein 
quantification was performed using Bradford Protein Assay Kit (Bio-Rad) according to 
manufacturer’s protocol. Protein preparation was run on 10% SDS-PAGE gel, followed by 
transfer to a nitrocellulose membrane. Membranes were blocked for one hour in 5% nonfat 
milk (Sigma) then incubated overnight with primary antibodies: AR (sc-816, Santa Cruz), 
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PSA (sc-7638, Santa Cruz), AhR (sc-101104, Santa Cruz), Mdm2 (sc-813, Santa Cruz), 
HDAC1 (sc-7872, Santa Cruz), GAPDH (sc-25778, Santa Cruz) and Cleaved PARP (#9542; 
Cell Signaling Technology), β-actin (Sigma). Membranes were then exposed with secondary 
antibody (anti-mouse/rabbit HRP; Dako) for an hour. The blots were washed then probed 
with ECL Prime Western Blotting Detection Reagents (GE Lifesciences).   
 
2.13. Cycloheximide (CHX) pulse chase assay.  
The prostate cancer cells were treated with DMSO, 30 µM icaritin, and 30 µM 
icaritin plus 10 µM MG132 (being added 30 minutes earlier than other agents) in the 
presence of 50 µM translation inhibitor CHX for 0, 1, 3, 6, 12 and 24 hours. The whole cell 
lysates were analyzed by Western blot assay with the antibodies specifically against AR (sc-
816, Santa Cruz) and β-actin. AR protein intensities were quantified by gel-pro analyzer 4.0 
and normalized with β-actin. The percentage of AR at indicated time relative to pretreated 
AR (0 hour) was plotted again indicated time. The slope of semilogarithmic percentage of 
AR over time was used for estimation of AR protein half-life (T1/2). 
 
2.14. Co-immunoprecipitation (Co-IP) assay 
10 µM MG132 was added for 30 minutes to the prostate cancer cells to prevent 
protein degradation before the addition of the vehicle, 5 µM of 3-methylcholanthrene (3MC), 
or 30 µM icaritin for two hours. Co-IP experiments were performed using the Pierce Co-
Immunoprecipitation Kit (26149, Pierce) according to the manufacturer’s protocol. Briefly, 1 
mg of protein lysates was pre-cleared using a control agarose resin to minimize non-specific 
binding. These lysates were then applied to columns containing 10 µg AR antibody (sc-7305) 
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covalently linked to resin and incubated overnight at 4 °C. Equal volumes of the lysates were 
applied to columns containing mouse IgG (sc-2025) linked resin and processed the same as 
the AR antibody coupling resin for negative controls. The co-immunoprecipitate was then 
eluted and analyzed by the western blot assay along with the 5% input controls.  
 
 
2.15. In vitro ubiquitination 
CWR22RV1 cells were transiently transfected with pCDNA3-HA-Ub (Addgene) by 
Fugene HD (Roche, USA) for 48 hours, followed by 24 hours treatment with DMSO 
(vehicle), 5 µM 3MC, and 30 µM icaritin. The cell extracts were harvested and subjected to 
Co-IP assays. AR antibody (sc-7305, Santa Cruz) was used to pull down the ubiquitinated 
AR and HA-probe antibody (sc-805, Santa Cruz) to be analysed by western blot. 
 
2.16. siRNA Silencing 
Cells of 50% confluency were transfected with ON-TARGET plus SMARTpool 
human AhR siRNAs (small interfering RNA) (Dharmacon Inc Thermo Scientific). 
Dharmafect 2 was used as per manufacturer’s instructions for transient knockdown of AhR. 
Briefly 4 µl Dharmafect 2 was resuspended in 200 µl of plain RPMI and the mixture (A). In 
another tube, 50 nM of siRNA was resuspended in 200 µl of plain RPMI (B). Both mixtures 
A and B were incubated for 5 minutes at room temperature. Subsequently, mixture B was 
added to mixture A and carefully mixed by pipetting followed by incubation at room 
temperature for 20 minutes. During incubation the media in the wells are replaced with 
complete RPMI1640 media, 1.6 ml per well. Following incubation, 400 µl of transfection 
66	  
	  
mix is added into each well. Following siRNA transfection for 24 hours the media is replaced 
with fresh media. 72 hours after transfection, the cells were incubated with icaritin for 24 
hours before analysis and western blotting was performed to confirm AhR knockdown 
efficiency. 
 
2.17. In vivo orthotopic implantation SCID model 
Male 6-8 week-old NOD CB17-Prkdcscid/J mice were purchased from the Jackson 
Laboratory (Bar Haror, ME) were used. Orthotopic implantation was performed as 
previously described [240]. Mice were anesthetized with intraperitoneal (i.p.) injection of 
ketamine and xylazine. A lower midline incision was made and the prostate exposed. 2 x 106 
LNCaP-luc or 1 x 106 CWR22RV1 cells in 50 µl of phosphate-buffered saline (PBS, pH 7.4) 
were injected into the left dorsal prostatic lobe. The formation of a ‘bleb’ was the sign of a 
satisfactory injection. The surgical incision was closed with wound clips. SCID mice were 
allowed to recover for one week before imaging was initiated. Tumor growth was measured 
by an IVIS® imaging system (Xenogen). Mice received D-luciferin (Xenogen) at 150 mg/kg 
in PBS by i.p. injection at 10 minutes prior to imaging. Mice were anesthetized using 
isofluorane (Abbott Laboratories) and placed inside the camera box and imaged from the 
ventral view. Images and measurements of bioluminescent signals were acquired and 
analyzed using Living Image® software (Xenogen). Regions of interest (ROI) from displayed 
images were drawn around the tumor sites and quantified as photons/second (ph/sec). Three 
weeks after tumor cells inoculation, tumor-bearing mice were randomly divided into four 
groups, with 12 mice in each group.  The mice in four groups received i.p. injection of 
icaritin (using a formulation of cremophor EL: ethanol: PEG 400: 0.9 % saline = 13: 7: 40: 
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40, v/v/v/v) at the dose of 0 (control) and 33 mg/kg three per week for 10 weeks. Tumor 
growth in mouse prostate was monitored by IVIS imaging at weekly intervals. Body weight 
was recorded weekly. For the CWR22RV1 xenograft, one week after tumor cells inoculation, 
tumor-bearing mice were randomly divided into two groups, with ten mice in the icaritin-
treated group and eight in the control group. The mice in the two groups received an i.p. 
injection of ICT at the dose of 0 (control) and 33 mg/kg thrice per week for 5 weeks. All 
mice were housed under pathogen-free conditions with a 12 hours light and 12 hours dark 
schedule and fed ad libitum with plenty of fresh clean water at all times.  
 
2.18. Post treatment analysis of orthotopically implanted SCID mice 
At the end of the experiment, the mice were humanely euthanized. 50 µL of mouse 
serum was obtained and serum PSA levels measured by the ClinPro PSA ELISA kit (ClinPro 
international Col LLC).  At harvest, primary tumors, swelling lymph nodes were removed, 
weighed (for primary tumors), snap frozen (half), and formalin fixed (half) for further 
analysis. Tumors were removed, photographed and measured by digital caliper and tumor 
volumes (including those from mice died earlier) calculated by the formula length x width2 x 
0.5. All animal experiments were performed humanely in compliance with guidelines 
reviewed by the Animal Ethics Committee of the Biological Resource Centre of the Agency 
for Science, Technology and Research.  
 
2.19. Immunohistochemistry and Quantitation  
After paraffin embedding, specimens were serially sectioned and stained with 
hematoxylin and eosin. The anti-AR (PG-21, Millipore), anti-Ki-67 (ab92742, Abcam), anti-
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VEGF (ab52917, Abcam) and anti-human mitochondria (ab92824, Abcam) were used for 
immunohistochemical staining on formalin-fixed 5 µm thick slides using a Bond Max 
autostainer (Leica Microsystems). For immunohistochemical quantification, five random 
digital images per slide at 1392 × 1040 pixel resolutions at 400 × magnifications were 
captured by an Olympus DP50 microscope (Olympus). Then image analysis software, Image 
Pro Plus 6.0 (Media Cybernetics, Inc., Bethesda, MD), was used for digital photographs 
analysis as described previously [241].  Briefly, the measurement parameters included area 
sum and integrated optical density (IOD). The optical density was calibrated and the area of 
interest was set through: AR staining (hue, 0 ~ 250; saturation, 0 ~ 120; intensity, 0 ~ 150), 
Ki-67 staining (hue, 0 ~ 100; saturation, 0 ~ 100; intensity, 0 ~ 140). Then, the image was 
converted to gray scale image. The mean density was the ratio between IOD and area sum.  
 
2.20. Detection of apoptotic bodies by TUNEL staining 
The paraffin-embedded tissue sections were deparaffinized, rehydrated, and then used 
to visualize apoptotic bodies by the TUNEL Apoptosis Detection Kit (GenScript, 
Piscataway, NJ) following the manufacturer’s protocol. The mean density of apoptotic bodies 
in five random digital images per slide at 1392 × 1040 pixel resolutions was determined 
using Image Pro Plus 6.0. 
 
2.21. Toxicity in tumor-free SCID mice 
Two groups of tumor-free SCID mice were i.p. treated with 33 mg/kg of icaritin 
solution (n = 10) and physiological saline (n = 5) three times per week for ten weeks. Body 
weight was recorded weekly. Mice were monitored daily for signs of toxicity. One day after 
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the last dose (the 30th treatment), the mice were weighed, sacrificed and necropsied. The 
whole blood of each mouse was collected by cardiac puncture for clinical chemistry and 
hematological evaluation using a biochemical autoanalyzer (Type 7170, Hitachi, Japan). The 
reference ranges were supplied by the National University of Singapore Vivarium at the 
Centre for Life Science, Singapore. Carcasses were perfused with cold 0.9% physiological 
saline and 4% buffered formalin. The heart, lung, liver, kidney, and spleen of each mouse 
were harvested, formalin-fixed, paraffin-embedded, hematoxylin and eosin (H&E) stained 
for histopathological examination. 
 
2.22. Statistical Analysis 
Statistical analysis was performed using SPSS 13.0 (SPSS Inc). Comparisons of 
tumor volumes, tumor BLI, serum PSA level, mean density of staining in tumor-bearing mice 
among more than two groups, were performed using one-way analysis of variance (ANOVA) 
followed by the Tukey’s tests for the post hoc multiple comparisons between individual 
groups. The Mantel-Haenszel chi-square test (Fisher’s exact test) was used to compare the 
incidences of lymph node and lung metastases development between vehicle and icaritin 
treated groups. The correlation between endpoint tumor BLI and tumor volume were 
determined using the Pearson correlation test.  Comparisons of body weight, hematological 
parameters, and clinical chemistry in tumor-free male SCID mice between 33 mg/kg icaritin 
and physiological saline treatments were made using Student’s independent-sample t-test. 
Data shown for all in vitro experiments are the mean (error bars, SEM) of three independent 
experiments. Comparisons were performed using Student’s independent-sample t-test. The 









Chapter 3: Antiandrogen icaritin acts as a modulator of 





3.1. Icaritin inhibits growth and induces apoptosis in human prostate cancer cells in 
vitro.  
Here we utilized several key models of human prostate cancer cell lines namely, 
LNCaP (androgen sensitive), CWR22RV1 (castrate-resistant cell line, which overexpresses 
ARvs), C4-2 (castrate-resistant subline of LNCaP) and VCaP (castrate-resistant cell line that 
overexpresses wildtype AR) to evaluate the effect of icaritin on cell growth. Icaritin 
markedly reduced cell proliferation in the four AR-positive prostate cancer cell lines as 
compared to the clinically-used bicalutamide, in a dose- (Figure 9A) and time- (Figure 9B) 
dependent manner in the presence of 1 nM or 10 nM DHT as indicated, mimicking the 
androgen-sensitive and the castrate-resistant states respectively.  Unlike bicalutamide that 
present agonistic properties in VCaP cells, icaritin did not promote cell proliferation at higher 
doses (Figure 9A, right panel). The effect of icaritin on the normal human prostate epithelial 
cells, RWPE-1 and WPMY-1 was investigated to compare the effects of icaritin between 
tumorigenic and non-tumorigenic cells. Notably, icaritin treatment had minimal inhibitory 
effects on growth of RWPE-1 and WPMY-1 cells (Figure 9A).  
 
To further characterize the loss of cell viability, cell cycle analyses were performed. 
The flow cytometric analysis demonstrated a dose-dependent increase in the hypodiploid 
sub-G1 phase indicative of DNA fragmentation, and possibly apoptosis following icaritin 
treatment in both LNCaP and C4-2 cells under androgen-replete and androgen-deplete milieu 
respectively (Figure 9C).  Consistently, treatment of prostate cancer cells with 30 and 50 µM 
of icaritin, noticeably induced poly-ADP-ribose polymerase (PARP) cleavage, a putative 
72	  
	  
apoptosis indicator, whereas bicalutamide did not (Figure 9D). Morphological assessment of 
the LNCaP and C4-2 cells following icaritin treatment revealed apoptotic-like characteristics 
including cell shrinkage, rounding up of cells, bleb formation, loss of contact with 
neighboring cells, and consequently detachment. This was in stark contrast to the untreated 
or bicalutamide-treated cells, which were epithelial like, polygonal in shape and adherent to 
the plates (Figure 9E). Put together, icaritin demonstrated a significant suppression of cell 
growth in the prostate cancer cells possibly in an apoptosis-dependent manner but exhibited 
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Figure 9. Icaritin (ICT) inhibits growth and induces apoptosis in human prostate 
cancer cells. A. Androgen-sensitive (LNCaP), and castrate-resistant (CWR22RV1, C4-2 and 
VCaP) prostate cancer cells were treated with ICT and bicalutamide (BIC), in the presence of 
DHT (10 nM, LNCaP; 1 nM, CWR22RV1, C4-2 and VCaP) for 48 hours. Normal prostate 
epithelial (RWPE-1) and myoblast (WPMY-1) cells were exposed to ICT and corresponding 
doses of DHT for 48 hours. Cell survival was assessed by the MTS cell proliferation assay 
and expressed as a percentage of vehicle (DMSO). All data shown are mean ± SEM of at 
least 3 independent experiments. *, p < 0.05; **; p < 0.01 compared to BIC-treated PCa cells.  
B. LNCaP, C4-2, CWR22RV1 and VCaP cells were treated with ICT or BIC for 0, 1, 3 and 5 
days at indicated concentrations (dashed line: 10 uM; solid line: 30 uM) with DHT (LNCaP: 
10 nM; C42, CWR22RV1 and VCaP: 1 nM). Cell survival was measured using MTS assay 
and expressed as a percentage of vehicle controls. C. LNCaP and C4-2 cells were treated 
with increasing doses of icaritin (ICT), in the absence or presence of DHT (LNCaP: 10 nM; 
C42: 1 nM), for 48 hours. DNA fragmentation cell cycle analysis as performed using flow 
cytometry. D. Prostate cancer cells were treated for 48 hours in a dose dependent manner 
with ICT or BIC with DHT (LNCaP: 10 nM; C42, CWR22RV1 and VCaP: 1 nM). Whole 
cell lysates were then prepared and PARP cleavage was analyzed by western blot. β-actin 
was probed as a loading control. E. LNCaP and C4-2 cells were treated with DMSO (Veh), 
ICT (50 µM) and BIC (50 µM) for 48 hours. Images were captured at 10 × magnification. 
Images were captured at 10 × magnification. All data shown are mean + SEM of at least 
three independent experiments.  
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3.2. Icaritin suppresses the transcription of AR regulated genes in prostate cancer cells 
and disrupts the AR transcriptional signaling. 
The AR acts via the AR-regulated genes to promote the survival/growth of prostate 
cancer cells. To determine whether reduced tumor cell proliferation by icaritin is 
accompanied by an inhibition of AR signaling, we tested the effects of icaritin on the levels 
of ten well-characterized AR-regulated genes transcripts in LNCaP, C4-2, CWR22RV1 and 
VCaP cells. In all the prostate cancer cells, icaritin antagonized DHT-mediated induction of 
mRNA expression of ten endogenous genes including PSA and TMPRSS2 (Figure 10A). 
Importantly, in VCaP cells that have endogenous AR gene amplification, icaritin did not 
promote the induction of AR-regulated genes, whilst bicalutamide treatment led to a dose 
dependent induction of several genes such as TMPRSS2, KLK2 and SLC43A1 (Figure 10A). 
 
Given that our data clearly shows that icaritin can inhibit androgen mediated gene 
expression, we next investigated the mechanism by which icaritin inhibits AR-regulated gene 
expression.  Androgen-dependent AR transcriptional activity has been shown to be regulated 
by several mechanisms, which includes modulating a) androgen binding to the AR LBD, b) 
AR amino- and carboxyl terminal (N-C) interactions, c) AR nuclear translocation, and d) AR 
binding with the DNA [242]. To that end, we firstly investigated if icaritin can compete with 
AR ligands to specifically bind to the AR LBD. In a competition-binding assay using HeLa 
cells stably transfected with AR, icaritin competitively displaced DHT with an IC50 of 3.9 
µM (Figure 10B). In comparison, bicalutamide bound to AR with an IC50 of 0.16 µM, a 
binding affinity that was approximately 24-fold stronger than icaritin. The stark contrast in 
the binding affinity of icaritin and bicalutamide to the AR LBD suggests that it is unlikely for 
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these compounds to share similar mechanisms to regulate AR transcriptional activity. Next, 
we studied the AR N-C interaction. Icaritin displayed a substantial disruption of the DHT-
stimulated AR N-C interaction in a dose dependent manner, albeit weaker than bicalutamide 
(Relative RLU: 17.2% for 50 µM Icartitin versus 5.3% for 10 µM bicalutamide, Figure 10C) 
suggesting that this could be a mechanism by which icaritin could elicit its effects. Given that 
translocation of AR to the nucleus is critical for DNA binding and subsequent AR dependent 
transcriptional activity, we assessed the effects of icaritin on the nuclear translocation of AR 
by confocal microscopy. Interestingly, icaritin significantly reduced DHT-induced AR 
nuclear translocation, unlike bicalutamide-treated LNCaP cells (Figure 10D). Quantitative 
analysis of the nuclear florescence for AR demonstrated that the percentage of nuclear AR in 
icaritin-treated cells was approximately a quarter of that in bicalutamide-treated cells (13.8% 
versus 49.2%, p < 0.01%, Figure 10D). We next assessed if icaritin can interfere with AR 
binding to a consensus androgen response element (ARE). For this purpose, we used HeLa 
cells stably transfected with AR and ARE-Luc reporter genes and LNCaP cells transiently 
transfected with ARE-Luc reporter genes. Icaritin suppressed DHT-stimulated ARE 
luciferase reporter gene activity in both cells (Figure 10E). Consistently, ChIP experiments 
showed that similar to well-documented bicalutamide activity [169], two hours treatment 
with icaritin blocked DHT-mediated AR recruitment to the enhancers or promoters of AR 
regulated genes, KLK3, KLK2, TMPRSS2, and FKBP5 (Figure 10F) in LNCaP and 
CWR22RV1 cells. Interestingly, this impairment of AR binding to DNA was reversed by 
MG132 in CWR22RV1 that is known to overexpress AR variant (AR-V7), but not in LNCaP 
cells (Figure 10F). These findings further suggest that the proteasomal-degradation pathway 
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may be another mechanism by which icaritin modulates levels of AR regulated genes in 

























Figure 10. Icaritin suppresses the transcription of AR regulated genes in prostate 
cancer cells and disrupts the AR transcriptional signaling. A. Quantitative RT-PCR 
analysis of ten AR-regulated genes normalized to 18S ribosomal RNA (18S rRNA). LNCaP, 
C4-, CWR22RV1 and VCaP cells were exposed to DMSO (Veh), icaritin (ICT) (10, 30 and 
50 µM) or bicalutamide (BIC) (10, 30 and 50 µM) with or without DHT (LNCaP: 10 nM, 
C4-2, CWR22RV1 and VCaP: 1 nM) for 24 hours. The expression of the AR-regulated genes 
is illustrated by the heatmap plotted using Treeview version 1.6. B. Representative 
competition binding curves showing inhibition of 3H-DHT equilibrium binding to AR by the 
presence of increasing doses (nM) of unlabeled DHT, BIC or ICT in HeLa cells stably 
expressing AR. C. Effects of ICT and BIC on AR (N-C) interactions were measured by a 
mammalian two-hybrid assay. CV1 cells were transiently cotransfected with pVP16-ARTAD 
(amino acids 1–565), pMGAL4-ARLBD (amino acids 628–919), pGL3-Gal4Luc reporter 
and a PRL-renilla reporter for 48 hours. Cells were next treated with DMSO (Veh), 10 µM of 
BIC or 10 and 50 µM of ICT in the presence or absence of 10 nM DHT for 24 hours. The 
dual luciferase reporter assay system was employed to measure the luciferase activity. D. The 
effects of ICT and BIC on DHT-stimulated nuclear translocation of AR in LNCaP cells as 
determined by confocal microscopy analysis. The cells were fixed and stained with rabbit 
anti-AR polyclonal antibody (green) and nuclei 2-(4-amidinophenyl)-1H-indole-6-
carboxamidine (DAPI, blue). Scale bars represent 10 µm in all micrographs (Left panel). The 
percentage of nuclear fluorescence intensity relative to the intensity in the whole cells was 
calculated based on the confocal microscopic images. Quantification of AR nuclear 
translocation was performed using an Olympus Fluoview FV1000 confocal system. Data 
shown are mean + SEM of at least 4 images (Right panel). E. HeLa cells stably transfected 
with AR and ARE-Luc reporter genes and LNCaP cells transiently transfected with ARE-Luc 
reporter gene were treated with increasing doses of icaritin in the presence of 10 nM DHT for 
24 hours. AR activity as indicated by luciferase reporter gene activity measured. F. 
Chromatin immunoprecipitation (ChIP) analysis of AR binding to the androgen-response 
elements (ARE) of KLK3, FKBP5, KLK2 and TMPRSS2 genes in LNCaP and CWR22RV1 
cells. LNCaP and CWR22RV1 cells were pretreated for 30 minutes with 10 µM of MG132 
following which they were treated with DMSO (veh), 30 µM ICT or 30 µM BIC in the 
presence or absence of DHT (10 nM for LNCaP and 1 nM for CWR22RV1) for 2 hours. 
Immunoprecipitated DNA was quantified using qPCR for specific binding sites. All data 










3.3. Icaritin induces proteasomal degradation of the AR protein in prostate cancer cells.  
Given that MG132 could partly reverse the inhibition of AR binding to the DNA of 
target genes, we next studied if icaritin can alter the stability of AR protein in prostate cancer.  
Notably, icaritin demonstrated a dose-dependent reduction in the levels of AR (~ 110 kDa) 
and AR-V7 (~ 80 kDa) in the prostate cancer cells (Figure 11A). However, bicalutamide did 
not cause a visible reduction in both AR and AR-V7 protein levels (Figure 11A), again 
suggesting differential mechanisms of action between icaritin and bicalutamide. 
Correspondingly, icaritin treatment also resulted in marked dose dependant reductions in 
prostate specific antigen (PSA) levels (Figure 11A). To assess if the effects of icaritin were 
limited to AR, or it extended to other nuclear receptors, we studied the effects of icaritin on 
the expression of other nuclear receptors. As we have demonstrated previously, icaritin 
induced a reduction of ERα protein content [226]. In comparison, peroxisome proliferator-
activated receptor gamma (PPAR-γ), glucocorticoid receptor (GR), progesterone receptor 
(PR), ERβ and AhR protein stability were not affected (Figure 11B). 
 
To further elucidate the mechanistic basis of action of icaritin on AR protein stability, 
a pulse chase experiment using a translation inhibitor cycloheximide (CHX), was performed. 
In comparison with vehicle-treated prostate cancer cells, icaritin treatments of prostate cancer 
cells markedly accelerated the rate of AR decay, thereby reducing AR half-lives by 
approximately 50% (Figure 11C and D). Interestingly, icaritin led to the degradation of AR-
V7 significantly faster than that of AR (2.4 h versus 5.7 h, Figure 11C and D). MG132 
reversed the icaritin-mediated AR and AR-V7 degradation in the prostate cancer cells, 
strongly suggesting that proteasomal degradation played a pivotal role in icaritin-mediated 
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AR degradation. We then assessed if the changes in AR and AR-V7 protein levels could be 
attributed to changes at the transcriptional level with icaritin treatment. However, no 


































Figure 11. Icaritin induces proteasomal degradation of the AR protein in prostate 
cancer cells. A. Prostate cancer cells were treated in a dose-dependent manner with icaritin 
(ICT) or bicalutamide (BIC) in the presence of DHT (LNCaP: 10 nM, other cell lines: 1 nM) 
for 24 hours. AR, PSA and β-actin (whole cell lystate loading control) were analyzed by 
western blotting. B. MCF-7, PC3 and CWR22RV11 cells treated with 0, 10, 30 and 50 µM 
icaritin for 24 hours. ERα, ERβ, PR, PPARγ, GR and AhR proteins were analyzed by 
western blotting. β-actin was used as loading control. C. The prostate cancer cells were 
incubated as indicated with DMSO (Veh), ICT and ICT plus MG132 in the presence of 50 
µM CHX for indicated durations. AR proteins intensities were measured by western blotting 
and quantified by gel-pro analyzer 4.0 and normalized by β-actin. The percentage of AR at 
indicated time relative to pretreated AR (0 hour) was plotted again indicated time for 
estimation of AR protein half-life (T1/2). Data are mean + SEM of 3 independent 
experiments. D. Representative blots of the prostate cancer cells incubated with DMSO 
(Veh), ICT and ICT plus MG132 in the presence of 50 µM cycloheximide (CHX) for 
indicated durations are shown. AR and β-actin proteins were measured by western blotting. 
E. qRT-PCR analysis of AR and AR-V7 was performed and normalized to glyceraldehyde-3- 




3.4. Icaritin destabilizes AR protein through AhR-mediated proteasome pathway to 
reduce cell survival 
The ubiquitin-proteasomal pathway is a key mechanism behind AR degradation [98, 
102], with Mdm2, an E3 ubiquitin ligase, reported to play an important role in the 
degradation process. With our findings clearly pointing to the proteasomal degradation 
pathway by which icaritin degrades AR (Figure 11), we set out to explore if AR degradation 
could be mediated in an Mdm-2 dependent manner. Firstly, we evaluated if icaritin can 
enhance AR-Mdm2 complex formation using co-immunoprecipitation (Co-IP). However, we 
did not observe any significant changes in AR-Mdm2 complex with icaritin treatment in 
LNCaP and CWR22RV1 cells (Figure 12A), suggesting that Mdm2 is unlikely to play an 
important role in the icaritin-mediated AR protein degradation.  
 
It has been reported that ligand-activated AhR can serve as an E3 ubiquitin ligase, 
leading to AR degradation [104]. Moreover, our group has previously shown that icaritin can 
bind to AhR via a competitive binding assay [226]. Thus, we examined if icaritin can 
modulate the gene expression CYP1A1, a key downstream target of AhR. Notably, icaritin 
induced a dose-dependent increase in the gene expression of CYP1A1 in LNCaP and 
CWR22RV1 cells (Figure 12B), suggesting that icaritin may serve as a ligand for AhR in 
these prostate cancer cells. Furthermore, treatment with icaritin and 3MC (a putative AhR 
ligand) clearly enhanced the association between AR and AhR proteins in the prostate cancer 
cells (Figure 12C), indicating that AhR possibly mediates AR degradation. To corroborate 
our findings, the effect of icaritin treatment on AR and AR-V7 expression was studied 
following AhR gene silencing. The dose-dependent destabilization of AR in LNCaP and 
CWR22RV1 cells and AR-V7 in CWR22RV1 cells by icaritin treatment could be abrogated 
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by AhR gene knockdown (Figure 12D). These findings clearly suggest an essential role for 
icaritin-activated AhR in the degradation of AR and ARvs in prostate cancer cells. 
Additionally, an in vitro ubiquitination analysis demonstrated that icaritin remarkably 
enhanced the poly-ubiquitination of AR and AR-V7 in icaritin-treated CWR22RV1 cells as 
compared to the vehicle-treated cells (Figure 12E). These findings suggested that the 
enhanced ubiquitination of AR and ARvs after icaritin treatment may be one of the key 
mechanisms to promote their degradation in prostate cancer cells.  
 
Next we examined the effects of AhR knockdown on icaritin-mediated cell death. As 
expected, AhR knockdown rescued the LNCaP and CWR22RV1 cells from icaritin mediated 
cell death by 20 to 30 % (Figure 12F) as compared to cells treated with a scrambled siRNA 
sequence. Put together, our data indicates that the suppressive effect of ICT on prostate 
cancer cell proliferation was mediated, in part, via AhR-dependent ubiquitin-proteasomal 
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Figure 12. Icaritin destabilizes AR protein through AhR-mediated proteasome pathway 
to reduce cell survival. A.  The interaction between AR and MDM2 in LNCaP and 
CWR22RV1 cells was analyzed by the Co-IP assay. The 10 µM MG132 was added for 30 
minutes to prevent protein degradation before the addition of the vehicle or 30 µM icaritin 
(ICT) for 2 hours. Whole-cell lysates were immunoprecipitated using an antibody against AR 
or control IgG, followed by western blotting with antibodies against AR and MDM2. Input is 
equivalent to 10% of the lysate used for the Co-IP. B. LNCaP, C4-2, CWR22RV1 and VCaP 
cells were treated with DMSO (Veh), 5 µM of 3MC, or 30 µM of icaritin for 24 hours. 
CYP1A1 mRNA levels were analyzed using qRT-PCR and normalized against 18S rRNA 
(n=3, mean + SEM).  C. The interaction between AR and AhR stimulated by 3-
methylcholanthrene (3MC) and ICT in LNCaP cells was determined by the Co-IP assay. The 
10 µM MG132 was added for 30 minutes to prevent protein degradation before the addition 
of the vehicle, 5 µM of 3MC, or 30 µM ICT for 2 hours. Whole-cell lysates were 
immunoprecipitated using an antibody against AR or control IgG, followed by western 
blotting with antibodies against AR and AhR. Input is equivalent to 10% of the lysate used 
for the Co-IP. D. LNCaP cells were transfected with siAhR or siScrambled for 72 hours 
followed by 24 hours treatment with ICT in a dose-dependent manner. Whole cell lysates 
were then subjected to western blot analysis of AR. β-actin was used as loading control. E. 
AR ubiquitination was measured by in vitro ubiquitination assay in CWR22RV1 cells. 
CWR22Rv1 cells were transiently transfected with pCDNA3-HA-Ub for 48 hours, followed 
by 24 hours treatment with DMSO (veh), 5 µM 3MC, and 30 µM ICT. Co-IP and 
immunoblotting were performed using antibodies against AR and HA tag. F. LNCaP and 
CWR22RV1 cells were transiently transfected with si-AhR or si-Scr for 72 hours. AhR 
protein levels were determined by western blot analysis. β-actin was used as a loading 
control (Left panels).  Following 72 hours silencing, cells were treated with ICT for 48 hours 
in a dose-dependent manner. Cell proliferation was measured using MTS cell proliferation 
assay (Right panels). Data shown are mean + SEM of 3 independent experiments. *, p < 
0.05, **, p < 0.01. 
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3.5. Icaritin inhibits growth of prostate cancer tumors in mice  
We next investigated the effects of icaritin in a physiologically relevant animal 
model. [243]. Human androgen-sensitive LNCaP-luciferase and castration-resistant 
CWR22RV1 cells were orthotopically implanted into the prostates of SCID mice. The 
progression and invasion of LNCaP tumor growth was studied in the presence and absence of 
icaritin. Bioluminescent imaging (BLI) in vivo indicated that intraperitoneal administration 
of icaritin (33 mg/kg) suppressed the growth of prostate cancer tumors from week 4 of 
treatment relative to controls (p < 0.05) (Figure 13A). After 10 weeks of treatment, there was 
10.6-fold increase in LNCaP tumor signal in mice in the control group. In contrast, mice 
injected with 33 mg/kg of icaritin saw a significantly lower 2.6-fold increase in tumor growth 
(Figure 13A).  
 
Consistently, LNCaP tumors harvested from mice of the icaritin group (250 ± 28 
mm3) were significantly smaller than those from control mice (861 mm3, p < 0.01, Figure 
13B). This result was also unequivocally observed in the castrate resistant CWR22RV1 
xenograft mouse model. Furthermore, there was a strong correlation between tumor volumes 
and endpoint BLI signal in LNCaP tumor-bearing mice (R2 = 0.732, Figure 13C). There was 
a relief of tumor burden by icaritin treatment, reduced weight loss in both the prostate cancer 
xenograft mouse models, (p < 0.05, Figure 13D) and improved survival rate of LNCaP 
tumor-bearing mice at the point of sacrifice (100% in icaritin-group versus 58% in vehicle-
group).  
 
Immunohistochemistry staining on excised LNCaP tumors revealed that i.p. delivery 
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of icaritin (33 mg/kg) significantly suppressed proliferation of LNCaP xenografts 
(proliferation marker Ki-67 positive cells: 20.3%) compared to vehicle control (64.3%, p < 
0.01) (Figure 13E, left panels). Consistently, icaritin treatment significantly increased the 
mean density of TUNEL staining compared to vehicle control (0.032 versus 0.008, p < 0.01), 
indicative of increased DNA fragmentation, hence apoptosis in these sections (Figure 13E, 
right panel). The western blot analysis demonstrated that icaritin induced more PARP 
cleavage as compared to vehicle control in CWR22RV1 xenograft tissues (Figure 13F). 
Overall, these findings indicated that icaritin reduction of tumor growth in mice was 








Figure 13. Icaritin inhibits growth of prostate cancer tumors in mice. A. in vivo 
bioluminescent imaging of five representative male mice harboring LNCaP-luc tumors at 
each group pretreatment and after 10 weeks’ treatment. Mice (n=12 per group) orthotopically 
implanted with LNCaP-luciferase cells were i.p. injected with vehicle control or icaritin 
(ICT) at 33 mg/kg thrice per week for 10 weeks and monitored bi-weekly using in vivo 
bioluminescent imaging (BLI) following i.p. injection of 150 mg/kg luciferin. Changes in 
tumor volume were measured as the bioluminescence in photons/second (ph/sec). Average 
BLI was plotted over weeks after tumor cell inoculation (n=12, mean + SEM). B. The 
representative images of tumors from three mice bearing LNCaP xenograft in vehicle- and 
ICT-treated groups are shown in left panel. Tumor volumes are plotted in the right panel 
(Mean + SEM). C. The correlation between endpoint bioluminescence of LNCaP xenografts 
and tumor volumes is calculated using the Pearson correlation test. D. Mean body weight-
time profiles were computed following treatment of intact SCID mice bearing LNCaP 
xenograft xenograft which were i.p. injected with vehicle control or ICT (33 mg/kg). Each 
value represents mean ± SEM. The vertical dotted line indicates the onset of the ICT 
treatments after 3 weeks of orthotopic LNCaP cells implantation. Statistical significance was 
computed between the ICT-treated group and vehicle-treated group at the end of the 10th 
week. E. Representative sections of primary LNCaP tumors were harvested from vehicle- or 
ICT-treated mice after 10 weeks of treatment, and IHC staining were performed for Ki-67 
(upper panel) and TUNEL (lower panel). Scale bars represent 50 µm in all micrographs. The 
percentage of Ki-67 positive cells and the mean densities of TUNEL staining were quantified 
using Image-Pro Plus software from the primary tumors, each with 5 randomly chosen 400 × 




3.6. Antitumor effect of icaritin is associated with reduced serum PSA and AR protein 
content  
 As PSA is an important biomarker for prostate cancer, we measured the levels of PSA 
in the serum from mice bearing LNCaP xenografts. PSA levels in mice treated with icaritin 
were lower compared to those administered vehicle (45.7 versus 86.5 ng/mL, p < 0.05, 
Figure 14A). Immunohistochemistry indicate that AR protein content was lower in LNCaP 
tumors exposed to icaritin (mean density: 0.086 for icaritin versus 0.123 for vehicle, p < 
0.05, Figure 14B). Icaritin also suppressed AR, AR-V7 and PSA protein in castrate resistant 
CWR22RV1 tumors (Figure 14C). These results further reiterate our in vitro findings that the 
growth inhibitory effects of icaritin on prostate cancer tumor growth could be mediated by 
































Figure 14. Antitumor effect of icaritin is associated with reduced serum PSA and AR 
protein content. A. Serum PSA levels were analyzed by ELISA in SCID mice bearing 
LNCaP tumors after 10 weeks of vehicle or 33 mg/kg icaritin (ICT) treatment (n=12, mean + 
SEM). B. Representative sections of primary LNCaP tumors were harvested from vehicle- or 
ICT-treated mice after 10 weeks of treatment, and IHC staining were performed for AR 
proteins. Scale bars represent 50 µm in all micrographs. (n=12, mean + SEM). C. The 
primary CWR22RV1 tumors from five vehicle- and ICT-treated mice after five weeks of 





3.7. Icaritin inhibits LNCaP tumor metastases and has favorable safety profiles  
After ten weeks of treatment, the incidence of lumbar lymph node metastases in the 
vehicle treatment (91.7 % of mice), as determined by macroscopic examination, was 
significantly higher than that observed in the icaritin groups (33.3 %, p = 0.009, Figure 15A 
and B). Anti-human mitochondria staining of lymph nodes validated that the cells were of 
human origin (Figure 15A, right panel inset). These results indicated that icaritin suppressed 
metastasis of LNCaP xenograft to lymph nodes in SCID mice.  
 
Histopathology, clinical chemistry, hematological evaluations, and body weight 
revealed minimal toxicological effects in healthy tumor free SCID mice treated with icaritin 


















Figure 15. Icaritin inhibits LNCaP tumor metastases and has favorable safety profiles. 
A. Gross anatomy of representative lumbar lymph nodes with metastatic foci (white arrow) 
in a mouse from the control group. The inset demonstrates the IHC staining for anti-human 
mitochondria performed on the lymph node metastases to validate the human prostate cancer 
origin. B. The lumbar lymph nodes with metastatic foci in mice were grossly checked by 
macroscopic examination at the end of ten weeks of treatment. The mice containing solid, 
dark-red, and enlarged lymph nodes were classified as mice with lymph node metastasis, and 
the number of mice with metastasis was tabulated. The incidences of lymph node metastases 
development was calculated using the Mantel-Haenszel chi-square test (Fisher’s exact test) 
between vehicle and icaritin (ICT) treated groups. C. Mean body weight-time profiles were 
computed following treatment of intact SCID mice i.p. injected with 33 mg/kg ICT (n = 10) 
or with the physiological saline (n = 5) thrice per week for ten weeks. Bars represents mean ± 
SEM. D. Representative sections (200 × magnifications) of heart, liver, spleen, lung and 
kidney were harvested at the end of experiment from mice receiving i.p. delivery of 33 
mg/kg ICT (top) or vehicle control (bottom), and H&E staining was performed. Scale bars 


















Clinical chemistry and hematological parameters in healthy SCID mice after 10 weeks 
of i.p. administration of physiological saline (n = 5) and 33 mg/kg icaritin solution thrice 
per week (n = 10).  
The hematological parameters evaluated were leukocyte counts (WBC), neutrophils (NEU), 
lymphocytes (LYM), monocytes (MONO), eosinophils (EOS), basophils (BASO), 
erythrocyte counts (RBC), haemoglobin (HGB), hematocrit (HCT), mean corpuscular 
volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), red cell distributive width (RDW), platelet count (PLT), and mean 
platelet volume (MPV). The following clinical chemistry parameters were evaluated: 
albumin (ALB), alkaline phosphatise (ALP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubin direct, bilirubin total (TBIL), creatinine (CREA), total 
protein (TP), and blood urea nitrogen (BUN). The results obtained from the drug-treated rats 






















In this study we provide evidence that icaritin exerted potent antiproliferative and 
proapoptotic effects on AR positive prostate cancer cells both in vitro and in vivo. Our data 
suggests that icaritin effectively suppressed AR-regulated gene transcription via two distinct 
mechanisms in AR-positive prostate cancer cells: (i) acceleration of the ubiquitin mediated 
proteasomal degradation of AR and AR variants, and (ii) disruption of AR transcriptional 
activity through the impairment of DHT-stimulated AR N/C interaction, AR nuclear 
localization, and AR DNA binding.  
 
The antiproliferative effects of icaritin on AR positive prostate cancer cells shown in 
this study cannot exclude the possible contribution of AR-independent cell death pathways. 
Indeed, icaritin has been previously reported to cause cell cycle arrest and depolarization of 
the mitochondrial transmembrane with no apparent apoptosis in AR negative PC-3 prostate 
cancer cells [234]. These findings suggest a fundamental difference in the mechanism of 
action of icaritin-induced antiproliferation between AR positive and negative prostate cancer 
cells. The ability of icaritin to target different type of prostate cells at diverse stages of 
prostate cancer progression is important as prostate cancer is composed of a mixture of cells 
(basal, intermediate and luminal) at various stages of differentiation [244]. The current ADT 
has been shown to diminish the majority of CK5-/CK8+ luminal epithelial cell (e.g. LNCaP 
and CWR22RV1) populations, while boosting basal epithelial and intermediate cell 
CK5+/CK8+ (e.g. PC-3) populations [244]. As such, cellular heterogeneity of prostate cancer 
offers a critical explanation for why current ADT would eventually fail. Thus the ability of 
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icaritin to inhibit a wider variety of prostate cancer cells at different stages of differentiation 
confers icaritin a significant advantage over currently available ADT. 
 
The AR-signaling axis has been shown to play a critical role in the progression of 
CRPC. This has driven the development of new ADT such as abiraterone and enzalutamide, 
which targets the full length AR, [169, 202, 245]. Unfortunately, the positive responses to 
these treatments are often short lived with AR signaling being reactivated. Recent work 
describing the discovery of the constitutively active AR variants which lack the LBD have 
generated significant interest, as these variants are constitutively activated in prostate cancer 
tissues, driving resistance against ADT such as enzalutamide [246]. Moreover, they may also 
present a compensatory mechanism when the full length AR is targeted. These findings have 
largely accelerated the need to identify the next generation of novel therapeutic interventions 
for CRPC that can target both the full length AR and AR variant. In this light, our findings 
demonstrating that icaritin can effectively target both AR and AR variant proteins via an 
AhR-mediated ubiquitin-proteasomal pathway (Figure 12) confers icaritin a significant edge 
for further development for prostate cancer therapeutics.  
 
At present, there are three documented small molecule inhibitors, namely, EPI-001, 
ASC-J9 and mahanine, which have also demonstrated this unique capacity to target both AR 
and AR variants [247-249]. EPI-001 and its analogs target the AR NTD by covalently 
binding to it. Similar to icaritin, ASC-J9 and mahanine accelerate the proteasomal 
degradation of AR and AR variants, albeit through different mechanisms. ASC-J9 augments 
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AR degradation by enhancing the association of AR-Mdm2 complex [248], whereas icaritin 
works uniquely via an AR-AhR complex (Figure 12).  
 
 Ohtake et al. have previously reported that the ligand-activated AhR promotes the 
proteasomal degradation of sex steroid receptor including ERα and AR [226]. Similarly, 
activation of AhR by an agonist TCDD also demonstrated a reduction in cellular AR protein 
levels and subsequently inhibited the growth of LNCaP cells [106, 250]. Notably, we have 
previously shown that icaritin is a novel AhR agonist, which can accelerate the proteasomal 
degradation of the sex steroid receptor ERα by inducing cross talk between icaritin-activated 
AhR and ERα [226]. In this study, our results clearly demonstrated that icaritin-activated 
AhR also targets AR and AR variants in prostate cancer cells (Figure 12). Importantly, the 
AhR gene silencing could restore tumor growth (Figure 4D) suggesting that icaritin-activated 
cross talk between AhR and AR plays a vital role in the growth inhibition of AR positive 
prostate cancer cells. 
 
In addition to proteasomal degradation, assessing the transcriptional activity of AR 
following icaritin treatment revealed another interesting observation. Though treatment with 
icaritin inhibited DHT-mediated AR recruitment to the enhancers or promoters of AR 
regulated genes KLK3, FKBP5 KLK2, and TMPRSS2, this inhibition could be restored in 
CWR22RV1 cells with MG132 (Figure 10) but not in LNCaP cells. Intrigued by this finding, 
we assessed the degradation rate of AR and AR-V7 with icaritin treatment. Notably, the 
degradation rate of AR-V7 (T½: 2.5 hours) was significantly faster than that of the full length 
AR (T½: 5-7 hours) (Figure 11) suggesting that the inhibition observed in the ChIP assay at 2 
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hours in LNCaP cells, which only has full length AR, was not likely due to degradation of 
AR. However, this inhibition could be in part attributed to impaired nuclear translocation of 
the full length AR that was observed with icaritin treatment (Figure 10). Conversely in 
CWR22RV1 cells, where AR-V7 is known to localize in the nucleus in the native state [160, 
251], 2 hours of icaritin treatment possibly resulted in the degradation of AR-V7 contributing 
to icaritin-mediated impairment of AR DNA binding to AR target genes, which could be 
reversed with MG132.  
 
Our findings in this study have also revealed several critical advantages that icaritin 
has over other known anti-androgens in disrupting AR transcriptional activity. Firstly 
icaritin, unlike bicalutamide, did not display any typical agonistic properties on AR target 
gene expression, or proliferation in the AR overexpressing VCaP cells (Figure 9). Secondly, 
in contrast to antiandrogens such as enzalutamide and ARN-509 that can induce AR nuclear 
translocation [249], and potentially contribute to the clinical failure of ADT, icaritin 
remarkably suppressed the androgen-induced AR nuclear translocation (Figure 10). Thirdly, 
icaritin could disrupt AR transcriptional activity by preventing the androgen-stimulated AR 
N/C terminal interaction. Despite the significant disruption of AR transcriptional activity 
with icaritin, it is noteworthy that a very weak binding affinity of icaritin to LBD was 
observed in the competition-binding assay (Figure 10). Due to its weak binding affinity to the 
AR LBD, we speculate that icaritin still may exert its effect through the LBD, however we 
cannot preclude the possible involvement of alternative mechanisms of actions. Although it 
is early to hazard a conjecture on the exact mechanism via which icaritin elicits the above 
mentioned effects on AR transcriptional activity, we speculate two possibilities; (i) icaritin 
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may target other functional domains of AR such as the N- terminal domain of AR, similar to 
the compound EPI-001 [249] or (ii) icaritin may interfere with AR nuclear translocation by 
perturbing AR nuclear import and export by blocking the association of AR with importin 
α/β complexes or enhancing by facilitating the binding of nuclear export signal on AR to 
exportin1/CRM1.Ran-GTP [252] respectively.  
 
While our findings underscore the therapeutic potential of specific AhR ligands such 
as icaritin in targeting AR, for prostate cancer therapy, it is critical to stress that the 
therapeutic potential observed with icaritin cannot be arbitrarily conferred to other AhR 
agonists. For example, the putative AhR agonist TCDD has been shown to suppress PCa 
proliferation at the cellular level. However, in a population study of Vietnam warfare 
veterans exposed to TCDD contaminated Agent Orange, an increased rate of prostate cancer 
incidence and malignancy was observed [253].  In this light, it is noteworthy to mention that 
the preclinical data with ICT on our 10-week intervention study demonstrated a highly 
favorable safety profile, and ICT was well tolerated in healthy animals as reflected by the 
lack of adverse effects on body weight, histopathology of organs, clinical chemistry, and 
hematological evaluations (Figure 15 and Table 1). 
 
The clinically used ADT treatment of patients at earlier stages of prostate cancer has 
been reported to increase the cancer-specific mortality by accelerating malignancy of prostate 
cancer cells [254]. Recent evidence indicated that enzalutamide or bicalutamide induces 
macrophage migration and prostate cancer cells invasion via pSTAT3-CCL2 pathway[255]. 
Given that metastasis is the major cause of cancer-related death, it is significant to note that 
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in this study, icaritin clearly suppressed the invasion of LNCaP xenograft to the lumbar 
lymph nodes in the SCID mice representing an added advantage over current ADT (Figure 
15). 
 
 In conclusion, we have shown for a first time, mechanistic evidence to demonstrate 
that this novel prenylflavonoid icaritin derived from Chinese medicinal herb Epimedium can 
effectively promote the proteasomal degradation of both AR and the AR splice variants, 
effectively target the AR transcriptional regulatory system, and consequently inhibit 
androgen-sensitive and castrate resistant prostate cancer growth, and impede metastasis. In 
addition, icaritin has demonstrated a satisfactory long-term safety profile and probable high 
therapeutic index. Together, this work provides the platform and preclinical evidence for the 
development of icaritin, as a promising compound for advanced prostate cancer therapeutics. 
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4.2. Future Work 
Our work on the identification of icaritin as potential drug lead for prostate cancer 
therapeutics described in this thesis and the success of the Sawyer group and other as 
mentioned in chapter one in predicting drug actions through molecular dynamic simulations 
is promising and raises hopes for the development of better antiandrogens. However, it is 
important to note that flaws in the docking method do persist as it employs rigid protein 
structures, which limit accurate predictions. Moving on, it would therefore be reassuring to 
have these computational models verified by crystallographic studies.  
 
4.2.1 Attempts to crystallise icaritin with AR complex 
In order to understand the binding mode of icaritin with AR LBD, attempts to 
crystallise a complex of AR LBD-icaritin were made. Obtaining this structure would help us 
gain insights into the antagonist mechanism of action which is currently unclear in the field. 
Thus a small-scale purification of His6-GST-AR LBD was performed to screen the 
expression of this protein with icaritin and other AR antagonist. As seen in Figure 16, small-
scale expression of AR LBD with various antagonists did not help improve the expression of 













Figure 16. Small scale expression of His6-GST-AR LBD with DHT and AR antagonist 
to check for protein expression. His6-GST-AR LBD was expressed and purified with 50 
µM of DHT and various antagonist as indicated above the gel. Proteins were loaded on an 
SDS-PAGE to determine protein expression. 
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The main bottleneck for crystallization of AR-antagonist complex has been their 
conformational instability leading to the inability to obtain stable and soluble protein. To 
overcome this bottleneck, protein engineering was adopted. We have previously solved the 
structure of another nuclear receptor, photoreceptor-specific nuclear receptor (PNR, NR2E3) 
using protein engineering by tagging the N-terminus of PNR with the MBP (maltose-binding 
protein) with a stiff NAAAEF linker to improve protein solubility and help crystallisation 
(Appendix) [256]. In order to increase the expression and stability of the apo form of this 
protein, fusion protein of His6-MBP-AR LBD and His6-MBP-AR LBD-MBP were generated. 
The addition of one MBP to the N-terminus did not help improve the stability of this protein 
(Figure 17A). There is one aggregation peak (peak one) and a peak that happens to be the 
size of the MBP tag. However, addition of MBP in the N-terminus and C-terminus of this 
protein actually gave soluble proteins (peak two) after size exclusion chromatography 
(Figure 17B). Fractions from peak two were pooled and concentrated. There was only 0.2 mg 
of proteins obtained from two litres of bacteria cells. Crystallisation screens were set up for 
apo protein and protein pre-incubated with icaritin screening different precipitating agents at 


















Figure 17. Size-exclusion chromatography of (A) His6-MBP-AR LBD and (B) His6-
MBP-AR LBD-MBP. Proteins were loaded on a SDS-PAGE to determine protein 
expression and purity. 
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Clearly, crystallographic study of AR LBD antagonist conformation has been 
challenging [79, 180] as the AR LBD remains unstable in the absence of an agonist during 
protein expression and purification (Figure 16 and 17). In addition, the antagonist-bound AR 
LBD remains complexed with the chaperones groEL, probably due to improper receptor 
folding [180]. Ways to help stabilize AR LBD in an antagonist conformation should be 
explored to help in crystallising the protein. Based on my preliminary work on AR LBD 
crystallization, we were able to overcome the protein stability issue. However, more 
condition and protein engineering needs to be explored to obtain good quality well-folded 
protein with better yield. 
 
While the AR LBP remains the primary target of small molecules, the focus of 
screens is beginning to shift to other functionally significant domains of the protein, such as 
the NTD, DBD, AF2, and BF3. Recently, by means of an in silico method, Helsen et al 
provided insights on the existence and importance of physical connectivity between AR DBD 
and LBD [257]. This information will give researchers another plausible interface for drug 
intervention. More detailed information on the structure of the full length AR would provide 
a complete picture necessary to understand interdomain interactions. Crystallisation of full 
length nuclear receptors remains a formidable challenge, and currently only two structures of 
nuclear receptors that include all functional domains have been solved by the Rastinejad 
group (HNF-4α homodimers (PDB: 4IQR) [258] and PPAR/RXR heterodimers [259] 
complexed with their DNA elements and coactivator peptides).  These structures have greatly 
expanded our understanding of the physical connectivity between LBD and DBD, which can 
be capitalized for the design of small molecule inhibitor.  
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With rapid advances in protein engineering and data collection/diffraction methods, 
including X-ray free-electron laser [260], we expect that the full-length structure of AR in 
antagonist conformation will eventually be solved. We believe that by capitalizing on various 
critical contributions to the understanding of the AR structure and function and advancement 
in crystallography techniques, the future of rational drug design for better antiandrogen in the 





A. The crystal structure of the orphan nuclear receptor NR2E3/PNR ligand binding 
domain reveals a dimeric auto-repressed conformation 
 
A1. Summary 
Photoreceptor-specific nuclear receptor (PNR, NR2E3) is a key transcriptional 
regulator of human photoreceptor differentiation and maintenance. Mutations in the NR2E3-
encoding gene cause various retinal degenerations, including Enhanced S-cone syndrome, 
retinitis pigmentosa, and Goldman-Favre syndrome. Although physiological ligands have not 
been identified, it is believed that binding of small molecule agonists, receptor 
desumoylation, and receptor heterodimerization may switch NR2E3 from a transcriptional 
repressor to an activator. While these features make NR2E3 a potential therapeutic target for 
the treatment of retinal diseases, there has been a clear lack of structural information for the 
receptor. Here, we report the crystal structure of the apo NR2E3 ligand-binding domain 
(LBD) at 2.8 Å resolution. Apo NR2E3 functions as transcriptional repressor in cells and the 
structure of its LBD is in a dimeric auto-repressed conformation. In this conformation, the 
putative ligand-binding pocket is filled with bulky hydrophobic residues and the activation-
function-2 (AF2) helix occupies the canonical cofactor-binding site. Mutations designed to 
disrupt either the AF2/cofactor-binding site interface or the dimer interface compromised the 
transcriptional repressor activity of this receptor. Together, these results reveal several 
conserved structural features shared by related orphan nuclear receptors, suggest that most 
disease-causing mutations affect the receptor’s structural integrity, and allowed us to model a 




Nuclear receptors (NRs) constitute a large family of DNA-binding transcription 
factors that modulate gene expression involved in an extremely broad spectrum of 
physiology. The complete human genome contains 48 nuclear receptors, which include 
classic endocrine receptors, adopted orphan receptors, and orphan receptors [1]. Over the 
years, much focus has been placed on the classic nuclear receptors, such as androgen, 
estrogen, and glucocorticoid receptors, whose physiological regulation by small molecule 
ligands has made them among the most successful drug targets. In contrast, the class of 
orphan receptors, for which no ligand was known when cloned, remains of enormous 
interest, as their physiological roles are still emerging.   
 
NR2E3 is an orphan nuclear receptor that is highly expressed in photoreceptor cells 
[261-263] and plays pivotal roles in photoreceptor development, differentiation, and survival 
[263-276]. The human retina contains ~5% cone and ~95% rod photoreceptor cells. Rods 
contain a single type of visual pigment, rhodopsin, for high-sensitivity low light vision. In 
contrast, human cones contain one of three alternative pigments (S-, M-, and L-opsins), each, 
which respond to short (S), medium (M), and long (L) wavelengths for color and bright-light 
high-resolution vision. In concert with other transcription factors, NR2E3 has a dual role to 
consolidate the rod fate of rod precursor cells: NR2E3 is associated with the promoters of 
both cone-specific genes, including the cone opsin genes, to repress their transcription, and 
rod-specific genes, including rhodopsin, to activate their transcription. The default state of 
photoreceptor precursor differentiation appears to be formation of S-cone cells, which is 
inhibited in rod precursor cells by NR2E3 repressor function [8,9,10,11,12,15]. NR2E3 is not 
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only expressed during photoreceptor cell differentiation, but rather is continuously expressed 
at high levels in mature retina [272, 273], consistent with its proposed additional 
neuroprotective function. 
 
NR2E3-null mutations cause retinal degeneration and lack of color vision in mice 
[265, 266, 270, 273], whereas various point mutations have been associated with enhanced S-
cone syndrome (ESCS) [267, 277-281]. ESCS is characterized by increased numbers of S-
cones and reduced or undetectable rod function [267, 277], which causes slow, progressive 
retinal degeneration that can ultimately lead to complete blindness [278]. Apart from ESCS, 
NR2E3 mutations have also been associated with clumped pigmentary retinal degeneration, 
recessive and autosomal dominant retinitis pigmentosa, and Goldman-Favre syndrome [266, 
278, 282-292]. NR2E3 is therefore a potential target for the treatment of different eye 
diseases. NR2E3 has also been linked to cancer as it regulates Phosphatase and TENsin 
homolog (PTEN) [293], p53 [294],  and estrogen receptor α [295].  
 
One key question for NR2E3 is whether its activity is regulated by ligands. While 
attempts to search for physiological ligands have been futile for this orphan nuclear receptor, 
13-cis retinoic acid and synthetic compounds (11A and 11B) were identified as agonist 
ligands of NR2E3 [296]. These compounds both stimulate Gal4 DNA Binding Domain–
NR2E3 LBD-dependent reporter gene expression and reduce the interaction of the LBD with 
the co-repressors Nuclear receptor Co-Repressor (NCoR) and Silencing Mediator for 
Retinoid or Thyroid-hormone receptors (SMRT) in yeast two hybrid experiments [297].  
Despite these efforts in ligand identification, NR2E3 functions predominantly as a ligand-
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independent transcriptional repressor in most cell based assays, for which the underlying 
structural mechanism remains largely unclear. In this study, we solved the crystal structure of 
an apo-NR2E3 LBD, which reveals an auto-repressed dimeric conformation that is required 
for NR2E3 repressor functions. 
 
A3. Results 
A3.1. Crystal structure of the NR2E3 LBD in an autorepressed conformation  
NR LBDs are characterized by a canonical fold, typically comprising 12 α-helices, of 
which the N-terminal helices are much less conserved and defined. To determine the domain 
boundaries of the NR2E3 LBD, we designed four LBD expression constructs with variations 
at the N-terminus, starting at either G159, G170, A180, or D192 of full length NR2E3 
(Figure A1). When expressed as His6 Glutathione S-Transferase (GST)- or His6Sumo-fusion 
proteins, all of them were poorly soluble and unstable. Expression with a non-cleavable N-
terminal Maltose Binding Protein (MBP) tag and C-terminal His6 tag yielded soluble proteins 
that gave crystals, but these crystals did not diffract X-rays. Based on the poor behavior of 
these proteins and the weak conservation of the NR2E3 LBD N-terminus, we predicted that 
the NR2E3 LBD might not have an N-terminal helix 1, which is a characteristic of the related 
orphan nuclear receptor Testicular Receptor 4 (TR4).  The N-terminal region of TR4 lacks a 
helical structure and instead adopts a long flexible loop that extends to the canonical helix 3 




Figure A1. Sequence alignment of NR2E3 with other orphan receptors (COUP-TFII, 
TR4 and TLX) in the NR2 subgroup family and predictions on their secondary 
structure. Constructs were designed with various N-terminal start points (G159, G170, 
A180, D192 and L217). Predicted α-helices are indicated as red cylinders below the 
sequences. Asterisks indicate the two charge clamp residues that are important for the correct 
positioning of coactivator LXXLL motifs in the cofactor binding groove. 
 
We thus designed an expression construct of NR2E3 (217-410), which lacks the N-
terminal region that corresponds to the flexible loop in TR4, as a fusion protein with a non-
cleavable N-terminal MBP tag and a C-terminal non-cleavable His6 tag. This fusion protein 
was expressed and purified to homogeneity in the absence of ligand (Figure A2A). The MBP 
tag when fused to a target protein can stabilize the target protein and greatly facilitate crystal 
formation of the fusion proteins [299-302]. As it is in our case, we readily crystallized the 
MBP-NR2E3 fusion protein in the P21212 space group and solved its structure at a resolution 
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of 2.8 Å by using the MBP and TR4 structures as the molecular replacement models (Figure 
A2B). The statistics of data collection and structure refinement are shown in Table 2.   
 
The crystal structure reveals a dimeric arrangement of the NR2E3 LBD (Figure 
A2B).  Each monomer consists of a canonical antiparallel three-layer α-helical sandwich fold 
comprising 8 alpha helices (H3-5, H7-H10, and AF2), with a disordered region between helix 
5 and helix 7 (Figure A2B and A2C).  The dimer interface is a parallel coiled-coil formed by 
the helices 10 of both monomers (Figure A2B).  Similar to the structures of the ligand-free 
orphan NRs TR4, Rev-erb, NUclear Receptor Related-1 protein (NURR1), Chicken 
Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII), Dosage-sensitive sex 
reversal, and Adrenal hypoplasia critical region, on chromosome X, gene 1 (DAX-1) [298, 
303-306], the apo NR2E3 LBD lacks a ligand-binding pocket.  Instead, the C-terminal part of 
helix 10 bends and collapses into the space that corresponds to the ligand-binding pocket in 
other NR.  This space is filled with hydrophobic and aromatic residues (W257, F261, I381, 
I386, F390 and F391) whose bulky side chains protrude into the cavity (Figure A2D) and, in 
this conformation, do not provide enough space to allow ligand binding.  
 
The kink in helix 10 and the subsequent collapse of the binding pocket of NR2E3 
allows the AF2 helix, which follows helix 10, to bind in the cofactor-binding site of the LBD.  
Hydrophobic interactions stabilize the AF2 binding in this position, with residues M400, 
L403, L404 and M407 in the AF2 helix forming Van-der-Waals interactions with residues 
from helix 3 and 4 (Figure A2E). As a result of the occupation of the cofactor-binding site, 
the AF2 helix would block the binding of either a coactivator or a co-repressor to the LBD 
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and would therefore be expected to inhibit the receptor’s activity (Figure A2F and A2G).  
Thus, the collapsed ligand-binding pocket and the blocked coactivator-binding groove 























Figure A2. Crystal structure of the NR2E3 LBD is in an autorepressed conformation. 
A. Purification of the MBP-NR2E3 LBD-His6 fusion protein. The molecular weight of full 
length MBP–NR2E3LBD-His6 is 63.6 kDa. B. Overview of the NR2E3 dimer. Each 
monomer is colored purple, with helix 10 (H10) colored cyan and activation function domain 
2 (AF2) colored yellow. C. Front and side views of the NR2E3 LBD monomer. The 
secondary structure assignment is labeled according to nuclear receptor testicular receptor 4 
(TR4). D. The ligand binding pocket space within the bottom half of the NR2E3 LBD is 
occupied by large hydrophobic side chains (shown in red stick presentation). E. Hydrophobic 
interactions of the NR2E3 AF2 helix within the cofactor-binding site. Positively charged 
surfaces are shown in blue, negatively charged surfaces in red, and the uncharged, 
hydrophobic groove in white. F. Overlay of the NR2E3 LBD structure with the SRC1 
LXXLL motif (in green) from the RXR structure (1K74). G. Overlay of the NR2E3 LBD 
structure with the SMRT LXXIIXXXL corepressor motif (in magenta) from the antagonist-




Table 2. Statistics for crystallographic data collection and structure refinement  
  
PDB code: 4LOG  
  
Data collection   
Resolution (Å) 30-2.70 
Space group P21212 
Unit cell, a, b, c (Å) 89.43, 184.94, 85.97 
Reflection, unique/total 38683 / 264280 
Completeness (%) 96.4 (76.8) 
Redundancy 6.8 (4.5) 
Rmerge (%) 8.5 (65.5) 
Intensity, I/σ 20.2 (2.0) 
Structure determination and refinement 
Resolution Range (Å) 30-2.7 
Protein residues 686 
No. of water molecules 180 
R/Rfree (%) 27.0 / 31.1 
r.m.s.d. bonds (Å) 0.0097 
               angles (°) 1.161 




A3.2. AF2 is important for NR2E3 repression  
Similar autorepressed features have been observed in the structures of the ligand-free 
orphan nuclear receptors Rev-erbβ (2V0V), COUP-TFII (3CJW), and TR4 (3P0U) [298, 304, 
306] (Figure A3A). Superposition of the NR2E3 LBD to that of the above orphan nuclear 
receptors shows a clear similarity with root mean square deviations (rmsd) of 1.88 Å (131 Cα 
atoms), 1.42 Å (147 Cα atoms) and 1.38 Å (153 Cα atoms) respectively. There are noticeable 
differences between Rev-erbβ and NR2E3 in the position of helix 7 and in the very C-
terminus, as Rev-erbβ lacks the activation function 2 helix (Figure A3A). In the absence of 
an AF2 motif, helix 11 provides a structural platform for the binding of the co-repressor 
NCoR1, which is crucial for the constitutive repressive activity of Rev-erbβ [306]. COUP-
TFII and TR4 LBDs are overall very similar to that of NR2E3, but differ in their AF2 
position (Figure A3A). We have previously shown that the AF2 helix is important for the 
transcriptional activation function of both COUP-TFII and TR4 [298, 304].  Since binding of 
canonical NR corepressors and coactivators occurs in the hydrophobic groove formed by 
helices 3, 4, and AF2 [307], we were interested to test whether mutations and deletion of this 
region can affect NR2E3 transcriptional repression. 
 
In order to correlate the observed structural features with NR2E3 function, we 
expressed the NR2E3 LBD (residues 192-410, Figure A3B) as a chimeric protein fused to the 
DNA binding domain (DBD) of the yeast transcription activator Gal4. This construct was 
transiently transfected into AD293 cells and its effect was tested on a Gal4-responsive 
reporter plasmid using a luciferase assay (Figure A3B). In agreement with previous studies, 
this construct functioned as a transcriptional repressor [261] [296] [308] and reduced basal 
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luciferase reporter activity in a dose dependent manner (4-5 fold reduction with 100 ng of 
NR2E3 expression vector; Figure A3C).   
 
To test the role of the AF2 helix for NR2E3 activity, we expressed a C-terminally 
truncated LBD (residues 192-400) that lacks the entire AF2 helix. Surprisingly, the AF2-
truncated LBD is expressed at the same level as the full length LBD, yet has strongly reduced 
repression activity (Figure A3E), suggesting that the AF2 helix is required for NR2E3 
transcriptional repressor activity. To pinpoint the amino acids involved in this interaction, we 
created a series of site-directed mutations to substitute hydrophobic residues (I220, L228, 
L229, V232, L235) along helix 3 and 4 against alanine and tested these constructs in cell-
based activation assays. Our data suggest that amino acids V232 on helix 3, L253 on helix 4, 
and the AF2 helix are important for transcriptional repression by this receptor. Since the AF2 
helix blocks access to the canonical cofactor-binding site, these results further suggest the 
intriguing possibility that the AF2 helix in the apo conformation sterically clashes with 
coactivator binding, while NR2E3-specific corepressors may still be able to associate with 























Figure A3.  Activation function domain 2 is important for NR2E3 repression. A. 
Superposition of the alpha-C helix traces of the NR2E3 monomer (blue) with those of Rev-
erbβ (red), Coup-TFII (green), and TR4 (orange). B. Schematic presentation of the domain 
structure of NR2E3 and of the transfection constructs. C. Gal4DBD–NR2E3LBD is a 
transcriptional repressor. AD293 cells were transiently transfected with either Gal4DBD (100 
ng) or Gal4DBD–NR2E3LBD (10, 30, 100 ng) expression plasmids. Transcriptional activity 
was measured as luciferase activity. Luciferase activity was derived by normalizing firefly 
luciferase values to Renilla luciferase values, which was used as internal transfection control.  
D. The corepressor hydrophobic binding groove is formed by helix 3 (H3), helix 4 (H4), and 
activation function 2 (AF2). E. Effects of AF2 deletion and V232A and L253A mutations on 
NR2E3 repressor activity (top). Below: Relative Gal4DBD–NR2E3LBD expression levels 
determined by anti-Gal4DBD immunoblot. The molecular weight of full length Gal4DBD–
NR2E3LBD is 42 kDa.   
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A3.3. NR2E3 transcriptional repression activity requires the formation of a functional 
dimer 
The formation of dimeric LBDs is one of the hallmarks observed in many NRs.  
Importantly, the NR2E3 LBD also forms dimers in solution as shown by size exclusion 
chromatography (Figure A4C). In order to determine the role of the NR2E3 dimer 
configuration in NR2E3 repressor function, we made single or combined mutations to 
replace two key residues of the coiled coil dimer interface with arginine (L372 and L375; 
Figure A4A and A4B). These residues are conserved in the related NRs COUP-TFII, TR4, 
and TLX (Figure A1) and predicted to compromise or abolish LBD dimer formation. To test 
this prediction, we cloned wildtype and mutant PNR LBD (amino acids 192-410) into pBind-
Gal4 and pVP16 vectors for mammalian two hybrid assays.  As shown in Fig. A4D, the 
mutant LBDs failed to produce specific reporter gene activity, suggesting that both the L372 
and the L375 residue are important for dimer formation. We then tested whether NR2E3 
repressor activity is affected when NR2E3 dimer formation is disrupted. As shown in Fig. 
A4E, single mutations of L372 and L375 to arginine reduced NR2E3 repression ability by 
>50%, and the double mutant L372R/L375R retained only 20-30% of the activity of the 
wild-type receptor. These results suggest that transcriptional repression by NR2E3 requires 
the formation of a functional LBD dimer, consistent with other studies that showed the 
functional form of full length NR2E3 is a dimer [261] [308], and indicate that L372 and 








Figure A4. NR2E3 transcriptional repression activity requires the formation of a 
functional dimer. A. Top view of the NR2E3 LBD dimer, showing the close interaction of 
L372 and L375 (red and orange stick models, resp.) from the helices 10 (cyan) in the dimer 
interface. B. A close-up view of the helices 10 in the dimer interface. C. Size Exclusion 
Chromatography for Bio-rad Protein Standard (left) and MBP-NR2E3 LBD (right). D. 
Mutation of helix 10 coiled coil interface residues abolished LBD dimerization in a 
mammalian two-hybrid assay. Reporter gene activation by Gal4DBD–NR2E3LBD and 
VP16AD–NR2E3LBD wildtype and mutant expression plasmids is shown as bar graph.  
Cells cotransfected with pBIND-Id and pACT-MyoD were used as positive controls. E. 
Effects of the mutations L372R, L375R, and the double mutation L372R/L375R on NR2E3 
repression activity (top). Below: Expression levels of wildtype and mutant Gal4DBD–
NR2E3LBD determined by immunoblotting. 
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A3.4. Computer-modeling predicts a ligand pocket in the active conformation of the 
NR2E3 LBD 
One of the goals of determining the NR2E3 structure was to determine whether it has 
a ligand-binding pocket and if its activity is regulated by a hypothetical ligand. As mentioned 
above, the ligand binding pocket of the structure we have solved is packed with hydrophobic 
residues and space in the pocket is further limited by the kink at the C-terminal end of helix 
10. The structure of the related nuclear receptor Retinoid X Receptor (RXR/NR2B1) LBD 
has been solved both in the apo state [309] as well bound to the RXR agonist 9-cis retinoic 
acid [310]. To illustrate possible conformational changes toward a hypothetical active 
NR2E3 LBD structure, we overlaid the NR2E3 LBD structure with both the apo- (Figure 
A5A) [1LBD] and agonist-bound (Figure A5B) [1FBY] RXR LBD structures. The core of 
the apo-NR2E3 structure is largely similar to that of the apo-RXRα structure, but differs 
substantially from the structure of the RXR LBD bound to its agonist 9-cis retinoic acid, in 
which helix 10 is fully extended (Figure A5B). Notably, 13-cis retinoic acid, an isomer of 9-
cis retinoic acid, exhibits at high concentrations limited NR2E3 agonist properties [296].   
 
To probe whether the NR2E3 LBD can accommodate a hypothetical ligand, we 
modeled an active conformation of the NR2E3 LBD based on the structure of the agonist 
bound-RXRα LBD (PDB code: 1FBY), which has 39% sequence identity with the NR2E3 
LBD [261].  The model of activated NR2E3 contains a ligand-binding pocket that is 
surrounded by the hydrophobic residues H221, F261, W257, M298, V302 and L389.  The 
pocket has a calculated size of 578 Å3 (Figure A5C and A5D), a space adequate to 
accommodate small compounds.  While 13-cis retinoic acid can be nicely fitted in the active 
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conformation pocket (Figure A5D), the space is not able to accommodate compound 11A, a 
synthetic NR2E3 activator [296].  This result is consistent with a recent proposal that 








Figure A5. Computer model of the active conformation of the NR2E3 LBD reveals a 
putative open ligand-binding pocket. A. Overlay of the apo LBDs of NR2E3 (purple) and 
RXR (green).  B. Overlay of the LBDs of apo NR2E3 (purple) and agonist-bound RXR (lime 
green).  The main difference between the ligand binding pockets lies in the extension of helix 
10 in agonist-bound RXR. C. Computer model (SWISS Model) of the NR2E3 LBD in an 
active conformation based on the agonist-bound RXRα structure, with helix 10 extended.  A 
ligand-binding pocket of 578 Å3 was found in this conformation. The pocket volume and the 
surface (grey mash) were calculated using the program VOIDOO. D. Close-up of the 
potential ligand-binding pocket in the active model of the NR2E3 LBD and its surrounding 
residues. E. 9-cis retinoic acid (ball model), which has limited NR2E3 agonistic properties 
[296], fits well into the modeled ligand-binding pocket. 
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A3.5. Disease-causing mutations in the NR2E3 LBD predominantly affect receptor 
structural integrity 
Single amino acid mutations in NR2E3 have been associated with various eye 
diseases, but the basis by which they affect NR2E3 function is unknown. To gain insight into 
the function of amino acid residues altered in patients, we mapped residues deposited in the 
Leiden Open Variation Eye Disease Database (www.LOVD.nl/eye) on the LBD crystal 
structure (Figure A6A and A6B) and determined the effect of these mutations on NR2E3 
repressor activity in a cell-based assay (Figure A6C). As described previously [312] [313], 
and confirmed here in another cell line, mutants L263P, R311Q, R336P, L353V, and M407K 
strongly reduced the transcriptional repressor activity of the NR2E3 LBD, consistent with 
these mutants being disease-causing. Patient mutations mapped mostly to helices 5, 7 and 9 
(Figure A6A and A6B). Surprisingly, altered amino acids were not located in regions 
involved in receptor dimerization, ligand binding, or the canonical corepressor binding site at 
the AF2 site, regions that we would expect to affect NR2E3 transcriptional repressor activity.  
In order to test if the lack of repressor activity was a result of poor protein stability, we 
analyzed protein expression levels by immunoblotting. Expression of the NR2E3 mutants 
L263P, R336P, and L353V was almost abolished and expression of the remaining mutants 
R309G, R311Q, R334G and M407K was strongly reduced, suggesting that these mutations 



















Figure A6. Structural analysis of disease-causing mutations in NR2E3. A. List of 
reported NR2E3 mutations found in patients with various eye diseases.  ESCS: enhanced S-
cone sensitivity syndrome, CPRD: clumped pigmentary retinal degeneration, ARRP: 
autosomal recessive retinitis pigmentosa. B.  NR2E3 LBD mutations found in patients 
mapped on the receptor.  The view is presented similar to the orientation shown in Fig. A2C.  
C. Effects of eye disease mutations on NR2E3 repressor activity.  Left panel: Reporter gene 
expression of Gal4DBD–NR2E3LBD wildtype and mutant proteins.  Right panel: Expression 
levels of wildtype and mutant Gal4DBD–NR2E3LBD determined by immunoblotting. 
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A4. Discussion and conclusion	   
NR2E3 has been one of the last few nuclear receptors for which no structural 
information exist and that are difficult for crystallization studies. In order to crystallize the 
NR2E3 LBD in the absence of ligands, we had to remove the N-terminal region of the LBD 
and fuse the truncated LBD to an MBP tag via a short and stiff linker. Fusion of MBP with a 
short linker has previously been used by us and others to promote crystallization of various 
target proteins [299, 300, 314-318]. Recently, it has been shown that T4 lysozyme and apo-
cytochrome b562RIL fused N-terminally [319] or inserted into a cytoplasmic loop [320-322] 
of several 7-transmembrane receptors promoted crystallization by replacing flexible regions 
and by providing crystallization contacts, suggesting fusion with a stable tag may be a 
general strategy for crystallizing difficult proteins.   
 
Use of these engineering approaches allowed us to determine the crystal structure of 
the NR2E3 LBD. The structure of the receptor in the ligand- and cofactor-free state revealed 
an autorepressed dimeric conformation. We confirmed dimerization by size-exclusion 
chromatography and mammalian two-hybrid assays and showed that dimerization occurs 
through formation of a coiled coil that involves key hydrophobic interactions by L372 and 
L375 of helix 10. Mutations of these residues abolished LBD dimerization in the two-hybrid 
assay and impaired repressor function of the LBD, providing support for the importance of 
LBD dimerization for NR2E3 activity. 
 
The auto-repressed conformation of the NR2E3 LBD is reminiscent of the 
conformations of the ligand-free LBDs of other orphan NRs, such as COUP-TFII, Rev-erbβ, 
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and TR4. In each of these LBDs, the corepressor binding site is blocked by the AF-2 helix 
and the hydrophobic part of helix 10 projects into the ligand binding pocket to stabilize the 
inactive LBD conformation. While these orphan receptors share similar folds, they are 
regulated by diverse mechanisms. This diversity is consistent with the lack of conservation of 
LBD surface residues, which are key drivers for protein-protein interactions, resulting in 
interactions with different sets of transcription factors and coregulatory complexes that lead 
to different functions and activities. 
 
Nuclear receptors carry out their diverse transcriptional functions through the 
recruitment of coactivators or corepressor [27] that bind to conserved overlapping binding 
grooves. Since AF2 blocks access to the cofactor binding site in the apo structure of NR2E3 
and other orphan NRs, corepressors must either bind to alternative or additional sites of the 
LBD or they must displace the AF2 helix in order for NR2E3 to function as an active 
transcriptional repressor. In the latter case, we would expect that AF2 deletion would 
increase repressor activity, just the opposite of what we have observed. While we cannot 
exclude the possibility that deletion of the AF2 helix compromised NR2E3 repressor activity 
simply due to gross LBD misfolding, we think this is unlikely as the expression of the AF2-
truncated LBD was unaltered (Figure A3E), in stark contrast to the strongly reduced 
expression of all disease-associated mutant LBDs (Figure A6C). We therefore favor a model, 
in which corepressors for NR2E3 can bind to sites other, or in addition to, the canonical 
cofactor-binding site. To date, the best characterized NR2E3 corepressor is Ret-Cor, which 
functions as specific and directly NR2E3-binding bridging protein to recruit a large 
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corepressor complex that contains histone deacetylases, Sin3A, E2F/Myb associated protein, 
and NCor [323].  
 
While the function of NR2E3 as a transcriptional repressor is well established, studies 
revealed that NR2E3 can also work as a transcriptional activator [274]. How NR2E3 can 
switch from a transcriptional repressor to an activator is currently poorly understood, but may 
involve three different mechanisms: (i) synergistic interactions with Neural Retina Leucine 
zipper (NRL), Cone-Rod homeo box (CRX), and Rev-erb α transcription factors [263, 270, 
274, 275], (ii) regulation by Protein Inhibitor of Activated STAT3 (PIAS3)-catalysed 
sumoylation [324], and (iii) binding of currently unidentified physiological agonists. Most 
NRs are converted from transcriptional repressors to activators by binding of small molecule 
agonists in their ligand-binding pockets. Potential non-physiological endogenous (13-cis 
retinoic acid) and synthetic (compounds 11A and 11B) agonists have been identified for 
NR2E3, but it is not clear if they can directly bind NR2E3 [297, 311]. Since the apo NR2E3 
LBD in our structure, similar to other ligand-free orphan NRs [298, 303, 304], lacked an 
open ligand-binding pocket, we used a modeling approach to probe whether an active NR2E3 
LBD conformation could contain a ligand-binding pocket suitable for the binding of small 
molecule agonists. Our modeled structure suggests that the NR2E3 LBD may be capable to 
adopt a structure similar to that of RXR bound to its agonist 9-cis-retinoic acid, with a ligand 
pocket of a size and shape suitable to accommodate the weak NR2E3 agonist 13-cis retinoic 
acid. Our structural analysis therefore indicates that NR2E3 may be able to be regulated by 
small compounds.  
143	  
	  
Finally, we have mapped disease-associated mutations on the LBD crystal structure.  
There is a clear discrepancy between our structure obtained by X-ray crystallography and 
previous NR2E3 LBD structure predictions [282] [312]. The crystal structure therefore 
provides the first accurate information on location and interactions of amino acid residues 
altered in disease. Eye disease-associated mutations that we analyzed were distributed over 
helices 5, 7 and 9 (Figure A6B). These helices are important to maintain the structural 
integrity of the LBD, and mutations mapped onto these helices likely destabilize the protein 
as the corresponding mutant proteins display severe to moderate expression defects (Figure 
A6C). 
  
In conclusion, we have solved the structure of the NR2E3 LBD in an auto-inhibited 
and ligand-free state, which allowed us to analyze molecular details of NR2E3 repression, 
including the importance of dimer formation and the unexpected requirement of activation 
function 2 in the cofactor-binding site for repressor activity. Currently, there is no treatment 
to restore vision in diseases linked to NR2E3 malfunction. The computer model of an active 
state NR2E3 LBD suggests that NR2E3 may undergo conformational changes to adopt an 
unobstructed ligand-binding pocket suitable for the binding of small molecule agonists. The 
structure presented here may therefore help to understand NR2E3 regulation at the molecular 
level and may aid in the search for physiological or therapeutic modulators for the treatment 




A5. Materials and Methods  
A5.1. Protein preparation 
The human NR2E3 LBD (NR2E3 residues 217-410) with C275S mutation was 
expressed as a MBP–NAAAEF linker–NR2E3 (217-410)–His6 fusion protein from the 
expression vector pETDuet1 (Novagen). Six liters of BL21 (DE3) cells were grown to an 
OD600 of 1, followed by an induction with 100 µM of isopropyl-beta-D-thio-
galactopyranoside (IPTG) at 16 oC. After overnight incubation, cells were harvested and 
resuspended in 100 ml of extract buffer (200 mM NaCl, 25 mM Tris, pH 8, 10% glycerol, 2 
mM β-mercaptoethanol, and 200 µl of saturated PMSF). Cells were lysed using a French 
Press with pressure set at 1,000 Pa. Lysates were centrifuged at 13,000 rpm for 50 min and 
the supernatant was loaded onto a pre-equilibrated 5 ml Ni-chelating Hi-Trap column 
(Amersham Biosciences). The column was washed with 100 ml buffer A (200 mM NaCl, 25 
mM Tris pH 8, 25 mM imidazole and 10% glycerol) and the fusion protein eluted with buffer 
B (200 mM NaCl, 25 mM Tris pH 8, 500 mM imidazole, and 10% glycerol). The eluted 
proteins was further purified by Superdex 200 gel filtration chromatography (Amersham 
Biosciences) in 200 mM ammonium acetate, 25 mM Tris, pH 8, 1 mM EDTA, and 1 mM 
dithiotreitol and concentrated to 5 mg/ml for crystallization. 
 
A5.2. Crystallization and data collection 
Crystals of the MBP-NR2E3 LBD-His6 fusion protein were grown at 20 oC in 
hanging drops containing 1 µl of the above protein solution and 2 µl of well buffer 
containing 7% polyethylene glycol 6000 (Sigma), 8% isopropanol, 10 mM Tris(2-
carboxyethyl)phosphine (TCEP) and 0.1 M sodium citrate, pH 5.6. Crystals appeared within 
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3 days and grew to a final size of 100-300 µm on day 7. Crystals were mounted and soaked 
in the mother liquor solution supplemented with 20% 2,3 butanediol for cryo-protection. All 
crystals were flash frozen in liquid nitrogen prior to data collection. 
 
A5.3. Structure determination and refinement 
The NR2E3 crystals formed in the P21212 space group (Table 1). The datasets were 
collected with a MAR225 CCD detector at the ID line of sector 21 of the Advanced Photon 
Source at Argonne National Laboratory (Argonne, IL). The observed reflections were 
reduced, merged, and scaled with DENZO and SCALEPACK in the HKL2000 package 
[325]. 
 
The CCP4 program PHASER was used for molecular replacement [326], with the 
TR4 LBD (PBD code: 3P0U) [298] as a search model.  The initial model was manually built 
and refined with CNS and the CCP4 program REFMAC [327]. All figures were prepared 
using PyMOL [63]. The pocket volume and surface area were calculated using VOIDOO 
[328]. 
 
During structure determination, molecular replacement solutions obtained from using 
MBP as an ensemble to search for 2 copies of MBP failed. We were only able to produce an 
interpretable electron density map for one MBP. Islands of electron density could be seen in 
the supposed area of the other MBP, but the density was not sufficient for us to solve the 
structure of a second MBP. However, the lack of clear density for the second MBP was not 
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due protein truncation/proteolysis during crystallization as washed crystals loaded on a 
denaturing SDS-PAGE clearly showed the intact fusion protein.   
 
A5.4. Mammalian two-hybrid assay and luciferase reporter assays 
The expression plasmids were constructed by inserting NR2E3-LBD (residues 192-
410) into the pBind-GAL4 vector and pACT-VP16 vectors (Promega). Transfections were 
performed in AD293 cells, which were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS. Cells were plated in 24-well tissue culture plates. 
After overnight incubation, cells were transfected with 100 ng of pBind-GAL4-NR2E3 LBD, 
100 ng of pGLuc-5, and 0.1 ng of pHRL-TK-RLuc in Opti-MEM using Extreme9 according 
to the manufacturer’s protocol (Promega). One day after transfection, medium was changed 
to fresh medium. Two days after transfection, lysates were collected and luciferase activity 
was measured using the Dual Luciferase Reporter Assay System (Promega). Firefly 
luciferase values were normalized to Renilla luciferase as an internal transfection control.  
Luciferase activities were measured using an EnVision Multilabel Reader (Perkin Elmer).  
All assays were performed in triplicate and presented with standard deviations. 
 
A5.5. Extraction of protein samples and Western blotting 
Protein extracts were prepared using the CelLytic MT Cell Lysis Reagent (Sigma) 
and protein concentrations were determined by Bradford Assay. Proteins from lysates were 
separated by 4-20% gradient SDS-PAGE, transferred to nitrocellulose membrane, and 




A5.6. Site Directed Mutagenesis 
Point mutations were introduced in pGAL4-NR2E3-LBD and pACT-NR2E3-LBD 
constructs using the QuikChange method (Agilent). All mutant constructs were confirmed by 
DNA sequencing. 
 
A5.7. Statistical Analysis 
Statistical analysis was performed using Excel. Comparisons were performed using 
Student’s independent-sample t-test. The statistical significance level was set to be p < 0.05 
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